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PART A: Preface 
 
My Role 
I completed both projects through a part-time secondment to the Monitoring, Evaluation and 
Research Unit (MERU) at the Cancer Institute NSW, between June 2010 and April 2011. This 
arrangement was formally endorsed by the Chief Cancer Officer. Both projects were 
supervised by Dr Stephen Morrell (statistical supervisor), and Ms Deborah Baker, Manager of 
MERU.  
Both projects were taken from the MERU workplan, using data from the NSW Central Cancer 
Registry (NSW CCR) and were not familiar to me beforehand. While the projects both used the 
same dataset, they were not related.  
The first project built upon previous work within MERU to explore patterns of second cancer 
occurrence for urinary cancers. The intention was to increase our knowledge regarding bladder 
cancers occurring as secondary primary cancers and publish the results as a journal article. A 
draft manuscript was completed and is currently in the process of review within the CINSW 
prior to being finalised and submitted.  
The second project was focussed on a particular issue that had been identified with coding of 
the degree of spread variable within the NSW CCR. The aim was to explore, test and report on 
a technique to address the issue. A report summarising the findings was completed and 
submitted to MERU. This focussed on lung cancer as a test case and the wider applicability of 
the technique to other cancers will now be explored further.  
This was my first exposure the Central Cancer Registry Dataset.  I completed both projects 
independently, seeking input where required to understand the dataset, coding, existing SAS 
programs and formats and discuss issues as they arose.  
 
Reflections on Learning 
Communication 
Both projects helped me develop communication skills in two key areas. Firstly, throughout 
the course of the projects, it was essential to negotiate time and communicate with key 
individuals to gain a thorough understanding of the database and existing resources such as 
supporting documentation, SAS codes and formats. For both projects, I drew heavily upon the 
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expertise of other biostatistical staff as well as key staff involved in the coding and 
management of the NSW CCR. Clear communication of my queries, including the background 
and context to the project was essential in gaining the information required.  
Secondly, both projects required me to communicate complex statistical concepts and results 
in written and graphical form, as well as verbally when presenting findings to my supervisors 
and others within the institute. One of the biggest challenges was doing so in a succinct 
manner and isolating the key results that most directly addressed the questions of interest.  
 
Work Patterns/Planning 
Given my part time working arrangements on these projects, setting work patterns and 
planning ahead were essential in allowing me to balance my time on the projects with my 
other quite different work requirements.  
Completing both projects within reasonably tight timeframes required self-discipline, 
motivation as well as a flexible approach. I set deadlines for sections of work as well as overall 
completion of the projects. However, I found that both projects included unanticipated 
complexities due to coding which meant that I had to revisit the scope of the projects in 
consultation with my supervisors and revise my approach and timeframes where necessary.  
Both projects have helped me to realise that working with administrative data often requires 
compromise and more questions can often be raised than answers generated. Within project 
1, it was only after gaining a more thorough knowledge of the dataset and the limitations of 
some variables that I felt that I could adequately design specific analyses that would address 
the research questions. This meant that the project evolved somewhat from start to finish. 
Similarly within project 2, understanding the complex relationships between variables within 
the NSW CCR was essential before being able to make informed decisions regarding the most 
appropriate approach to be taken. Both projects have generated many new questions and it 
was difficult at times to contain the scope of the projects within a manageable limit.  
Statistical Principles, methods and computing 
The Central Cancer Registry was the main dataset used within both projects. This dataset is 
population-based and aims to capture all registrations of invasive cancers for NSW. The 
importance of this dataset is in monitoring trends in cancer registrations over time and as such 
it requires a census of cancer registrations rather than a sample and requires rigid and 
consistently applied data collection procedures.  
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Both projects gave me a very good insight into the importance of understanding the NSW CCR 
data collection and coding practices in detail. While some variables on the NSW CCR are 
reasonably straight-forward, others such as coding site of cancer, histology of cancer and 
degree of spread are governed by complex international classifications and coding rules. 
Additionally, the information provided from notifying sites for these variables is not always of 
sufficient quality to be able to code as accurately as would be desired. Communicating with 
experts from both a pathology and coding perspective was essential to understanding and 
using these variables in a valid and informative manner.  
It is also essential that inferences related to trends in cancer registrations are made with 
reference to trends in the underlying population. As such, population estimates from the 
Australian Bureau of Statistics (ABS) are an important component of any population-based 
cancer estimates.  
 
Project 1
Another important epidemiological principle for this project was the concept of “person years 
of observation”. When monitoring a population for the occurrence of a particular 
disease/event it is very important to consider the time period for which they were at risk of 
the event. For this project the event of interest was a second cancer and people were at risk 
from the time they entered the registry (at diagnosis of a first cancer) to the time they died, 
were diagnosed with a second cancer or until the end of the follow-up period. It was essential 
that time of death could be taken into account as this was highly likely to be related to the 
type of cancer with which they were initially diagnosed.  
 
Project 1 examined patterns of increased risk of a second cancer among those with a prior 
diagnosis of kidney cancer compared to the general population. The ability to draw a 
comparison between this sub-group and the underlying population was only possible because 
of the population based approach of the NSW CCR.    
Two main statistical methods were employed in this project: (i) the calculation of Standardised 
Incidence Ratios (SIRs); and (ii) Survival Analysis. Both were chosen because of their ability to 
account for biases in person years of observation due to data censoring. However, the first 
technique allowed examination of patterns of second cancers and to compare these with the 
underlying population, while the second was used to examine predictors of second cancer 
occurrence within a sub-group of people who had a specific cancer diagnosis.  
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I had come across the concept of SIRs previously within epidemiology courses undertaken and 
within journal articles and understood the principle of the calculation, although I had not 
previously undertaken such calculations using the retrospective cohort approach. I had access 
to a SAS program that had been previously created within MERU to calculate SIRs on CCR data, 
so did not need to start from scratch. However, in order to make any modifications to this 
program I needed to understand in a reasonable amount of detail how it worked.  
In undertaking the survival analysis component, I drew heavily upon the survival analysis unit I 
had completed in first semester 2010. There were some major differences though when 
undertaking this type of analysis on a large-scale administrative dataset. The potential length 
of survival time was much longer than any previously encountered, and because the CCR has 
now been operating for almost three decades, the potential issues with data inconsistency on 
some variables were much more complex than I anticipated. A major challenge with this part 
of the analysis was maintaining a connection to a relevant clinical or epidemiological question 
while balancing this with the limitations of the data.  
Comparing these two techniques provided a very good insight into the benefits and limitations 
of each. While SIRs provided a very good overview of elevated risk of a second cancer 
compared to the population level this technique could not be used to examine the significance 
of covariates in predicting second cancers within the population sub-group. A clear example of 
this was the relationship between sex and occurrence of bladder cancers following initial 
upper urinary tract cancers (eg. of the renal pelvis). SIRs showed the occurrence of bladder 
cancers to be much more markedly elevated for females compared to males. However, 
survival analysis showed that there was no difference between males and females in the rate 
of second cancer occurrence. SIRs were influenced by the underlying sex-specific population 
incidence of both first and second cancers whereas survival analysis only took account of sex-
specific incidence of second cancers within the population of interest. This was an important 
lesson in drawing conclusions from each technique. 
One of the major challenges I faced when commencing this project was using SAS for all 
analyses. While I had used SAS previously, including for multivariate analyses, there had been a 
period of at least two years where my use of SAS had been limited with use of other software 
packages instead during this time such as STATA. This was particularly an issue in conducting 
survival analysis which I had only ever previously undertaken in STATA and in which the BCA 
Survival Analysis unit I had completed was entirely based. I could have taken the option of 
installing STATA and using this, but chose to persist with SAS given it is so widely used at 
CINSW and there were existing SAS resources for CCR data such as programs and formats that I 
6 
 
could draw upon.  While SAS provided powerful options for the programming required for SIR 
calculations and also survival analysis, I found generating useful data and plots to assess model 
diagnostics to be less elegant and more time consuming within SAS compared to STATA.  
 
Of particular importance in project 2 were the principles of random and non-random variation 
and, in terms of missing data, the differences between Missing Completely at Random (MCAR), 
Missing at Random (MAR) and Missing Not at Random (MNAR). The issue under investigation 
involved data with a partially known missing data mechanism. The missing data was within a 
discrete period of time; however it was also related to the notification method used.  
Project 2 
It was evident that for many variables being investigated, including the main variable of 
interest degree of spread, there had been non-random variation in coding and notification 
practices over time. The use of imputation to address missing data assumes the data are not 
MNAR, therefore considerable deliberation was required to choose an approach that best 
reflected this assumption based on the known relationships between variables. However, it 
was also important to clearly articulate where assumptions had been made.  
In building a valid logistic model, it was important to consider the predictive power of the 
model. To do so, I drew upon principles of test evaluation which consider the sensitivity and 
specificity of a test in predicting an outcome. This provided a useful basis for assessing in what 
contexts the imputation process may be valid and where caution may need to be exercised in 
using this approach.   
The main statistical methods employed within this project were focussed on two areas: (i) 
categorical data analysis, using chi-square tests and logistic regression; and (ii) data imputation 
using Proc MI in SAS. Additionally, to validate the effect of the imputation process, modelling 
of imputed results against ‘test’ cases was conducted, and Kaplan-Meier survival curves were 
constructed.  
The first part of this project required building a logistic regression model to predict whether a 
lung cancer case had localised or unknown degree of spread. For the model building process, I 
drew upon courses such as Categorical Data and Generalized Linear Models. However, in most 
courses model building focussed on investigating relationships between covariates and an 
outcome variable rather than on predictive power. The process of building a model, given the 
specific aim and data limitations within this project, was a balance between gaining predictive 
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power and gaining consistency across the two variables that were related to the missing data 
mechanism: time period and notification method. This process reinforced the opinion that 
model building is not an exact science and that many different choices could be made. The end 
result was achieved by finding a model that could be defended as appropriate given the 
assumptions, but also provided adequate prediction. This was a much more difficult process 
than I originally anticipated.  
While missing data were acknowledged in many of the BCA courses as being problematic in a 
real world setting, no course specifically addressed the issue. In practice, there is often no ideal 
solution to addressing the issue and instead the best option must be chosen based on the 
extent of the problem and the type of mechanism causing the missing data. This project 
highlighted the importance of getting the data collection process right in the first place so as to 
avoid complex missing data patterns. Multiple imputation appeared a useful tool to address a 
complex missing data problem, but it was clear in the current project that the usefulness of 
this approach is dependent on understanding the missing data pattern and being able to 
construct a valid predictive model. 
SAS was used for all analyses with graphs produced either within SAS or via Excel. A variety of 
different procedures were used including Proc Logistic, Proc MI, Proc MIanalyze and Proc 
Lifetest. Much of the investigation of potential predictors was quite repetitive and one of the 
main time-saving mechanisms I developed was to output files directly to excel using the output 
delivery system (ods) within SAS. I also explored this approach for directly outputting graphs 
required for the report, but in the end found it quicker and more effective to produce the 
graphs within excel from the outputted data using a graph template. I would like to develop 
further my knowledge and expertise with using the output delivery system, as can see many 
advantages, both in terms of saving time and setting up efficient and standardised processes 
for running routine or repetitive data analysis.  
The Proc MI and Proc MIanalyze procedures were new to me for this project and I relied 
heavily on the SAS documentation to understand how to correctly apply these procedures. The 
missing data mechanism within this project meant that I had to think creatively about how to 
adapt the procedure to use prototype cases from one period of time to predict values for 
missing data in another period.  
 
Teamwork 
Communication with other team members 
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To complete both projects I drew upon the expertise of multiple other people within MERU 
and also within the Central Cancer Registry. I built key relationships with the biostatistics team 
to ensure correct understanding and use of databases, SAS programs and SAS formats. In 
particular, for project 1 this included the understanding of the SAS program for creation of 
SIRs. I found the most efficient way to work with this team was to outline my queries in writing 
via email and then book meeting times when necessary to go through processes or code in 
more detail.  
I also liaised with the coding manager and consultant pathologist advising on coding for the 
Central Cancer Registry. For project 1, communication with the consultant pathologist in 
particular was essential in gaining an understanding of the cell types and histological sub-types 
of cancers and also for assessing the relevance of particular questions to the clinic. For project 
2, the coding manager was an essential resource to understanding current and past coding 
practices for the degree-of-spread variable. I was extremely fortunate that she has been 
involved with the NSW CCR for many years, including during the 1990’s when the data 
collection issue for degree of spread occurred.  
Communication on progress with my supervisors was conducted mostly by email with regular 
meetings scheduled every two-three weeks. Again the most effective means of communicating 
was to ensure material was sent in advance and flag any particular questions for discussion. 
 
Negotiating Roles and Responsibilities 
As I was the only resource for both projects, there was little need to negotiate roles and 
responsibilities for the key tasks within the project. However, as the projects proceeded there 
was continued communication with my supervisors on the progress made and where input 
was required from others. This input was mostly in the form of expertise/advice or feedback. 
For project 2, I required assistance with correct extraction and creation of a variable that 
would provide me with the method of notification. This required negotiating some time with 
one of the biostatisticians during a very busy period.   
As I was only seconded part time to work on this project, I also needed to negotiate carefully 
with my Director as well as supervisors to ensure everyone was comfortable with the amount 
of time I would be allocating to the projects and other tasks. This continued throughout the 
projects as needed.      
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Working within timelines 
I initially set my own timelines for the projects in consultation with my supervisors. I worked 
on the two projects in sequence, setting a deadline for project 1 in November 2010 and a 
deadline for project 2 in April 2011. The tight timeframe for project 2 was necessitated due to 
my personal circumstances, as I discovered I was expecting a baby in May 2011.  Further 
consultation and discussion regarding project 1 has continued since November, with some 
further revisions planned for the manuscript prior to submitting this to a journal for publishing.  
The main mechanism for adhering to timelines was preparing a plan in advance of what 
milestones would be reached by each supervisory meeting. Timeframes required re-setting 
slightly and the scope of the projects required adjusting once work commenced due to un-
anticipated complexities in the coding of data. For project 1, this meant that more time was 
spent up-front understanding the issues so as to avoid incorrect or misleading use of the data. 
So as to still complete within the timeframe and provide a better focus for the project, it was 
decided that some analyses initially included in the project scope were better left out of the 
final manuscript. These will be followed up separately. For project 2, after initial exploration of 
the data and relationships between variables it was decided that some extra input from one of 
the other biostatisticians was required to create a variable that indicated the notification 
method for cases as this was a key aspect of the missing data mechanism. As it was a very busy 
period for the biostatistics team, this meant timelines had to be adjusted to fit with their 
workload.   
One of the major challenges in keeping the projects on time was that as well as my own part-
time input into the project, one of my supervisors was only available two days per week and 
the consultant pathologist was only available one day a week. This meant that planning of 
meetings had to be made well in advance to ensure input from all people.  
 
Helping others to understand statistical issues 
As I worked independently on both projects my main focus was on ensuring that I understood 
the statistical issues and could communicate these to my supervisors in a clear and informative 
manner. Prior to meetings, I wrote a summary of the issues and my proposed response to the 
issues so that we could then discuss the alternatives in an informed manner. Additionally, 
when meeting with others, such as the coding manager or other biostatisticians, I tried to 
summarise the problem I wanted to discuss in a very concise manner. I found in many 
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circumstances being able to graphically represent the problem was the most effective way to 
do this, particularly for discussions with the non-biostatisticians.  
In preparing the manuscript and report that resulted from these projects, I focussed on trying 
to clearly communicate the statistical issues involved and provide a clear explanation for the 
approach taken. For example, in the report for Project 2, I included a discussion regarding the 
background to the NSW CCR and the different types of missing data to try to provide some 
context to the problem being addressed.  
 
Ethical Considerations 
At the beginning of these projects, I ensured I was familiar with the NHMRC National 
Statement on Ethical Conduct on Research Involving Humans and also the NSW Health Act and 
Privacy Act to understand the context in which NSW Cancer Registry data is collected and how 
this fits within the National Statement. Both projects utilised NSW CCR data only and did not 
require any identifiable variables or data linkage. They were carried out within the remit of the 
core functions of the Monitoring Evaluation and Research Unit at the CINSW, and as such, 
were determined to be low risk projects that did not require ethical review.  
However, I was still conscious of my obligations in maintaining the confidentiality and privacy 
of the data. This included ensuring that data security was considered by carrying out all 
analyses within password protected secure servers at the CINSW. It also included 
consideration of confidentiality in reporting. As some of the combinations of cancers under 
investigation had few observations, the decision was made to report any cells with values less 
than 5 as approximate only (ie. “<5”). 
Throughout the project I was also aware of my professional responsibility to carry out accurate 
analyses and provide correct and relevant interpretation. This was especially important after 
uncovering certain limitations with the coding of the data and I made it a priority to 
understand these limitations in detail, adjust the analyses accordingly, and report the 
limitations of the study.    
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PART B: Project 1 – Bladder and non-bladder urinary cancers: 
examining patterns and risk factors for second cancers using data 
from the New South Wales Central Cancer Registry (Australia) 
Location and Dates: 
 
Cancer Institute NSW, Sydney, June-November 2010 
Context: 
 
This project was completed as part of the approved program of work 
within the Monitoring Evaluation and Research Unit at the Cancer 
Institute NSW. Heidi was seconded to MERU from another area of 
the CINSW to work on this project on a part-time basis. This project 
extended previous work completed within MERU assessing the 
excess risk of second primary cancers following an initial primary 
cancer diagnosis.  
  
Contribution of 
student: 
 
Heidi completed all review of literature, design of study, analyses, 
and write-up/presentation of results.  The calculation of SIRs utilized 
an existing SAS program created within the CINSW. The Survival 
Analysis component was completed independently.  
 
Statistical issues 
involved: 
 
• Calculation of Standardised Incidence Ratios (SIRs) 
• Kaplan-Meier survival analysis 
• Cox Proportional Hazards Regression 
 
Declaration: I declare that I have undertaken this project independently and have 
not submitted this work for previous academic credit.  
Signed:  
 
 
 
Supervisors Name: 
 
Dr Stephen Morrell (Co-supervisor with Ms Deborah Baker) 
Statement: This is to state that Heidi Welberry has conducted the statistical 
analyses, as outlined above, and writing for this project 
independently and in a very competent manner. After reading the 
relevant literature, Heidi has also conceived the research questions 
for the project in terms of the relevant issues. Consequently, the 
work has a high probability of being publishable. 
 
 
Signed: 
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Bladder and non-bladder urinary cancers: examining patterns and risk factors for second 
cancers using data from the New South Wales Central Cancer Registry (Australia) 
Introduction 
Study of the incidence of second primary cancers can be informative in identifying cancers 
with common etiologic factors or cancers that may arise as a consequence of treatment for the 
initial primary cancer. Following kidney cancer, the observation of excess invasive cancers of 
the bladder previously has been reported using data from the NSW Central Cancer Registry for 
the period 1972-1991 (1). McCredie et al. reported an elevated risk of invasive bladder cancer 
following cancer of the renal parenchyma in women only (Risk Ratio (RR)=3.4, 95% CI=1.1-8.0), 
and an elevated risk of invasive bladder cancer following cancer of the renal pelvis in both men 
(RR=8.7, 95% CI=5.4-13) and women (RR=39, 95% CI=26-56). They postulated that the pattern 
of excess cancers following cancer of the renal pelvis supported tobacco as a common risk 
factor, but not for cancer of the renal parenchyma. They suggested that the increased 
elevation of risk of bladder cancer in women reflected the high incidence of analgesic-
associated disease from use of products containing Phenacetin.   
The renal parenchyma and the renal pelvis have distinctly different morphological features. 
The renal parenchyma comprises nephrons, the functional tissue of the kidney, and cancers 
occurring in this region are most commonly renal cell carcinoma.  The renal pelvis acts as the 
funnel for urine flowing to the ureter and comprises urothelial tissue. Urothelial tissue (the 
urothelium) covers the surface of the urinary tract from the renal pelvis through the ureter 
and the bladder to the proximal urethra. The urothelium is characterized by transitional cells, 
and in Western countries more than 90% of cancers of these organs are transitional cell 
cancers (2). Another characteristic of urothelial tumors is that they are frequently multifocal in 
nature, commonly occurring either synchronously or asynchronously in different regions of the 
urothelium.  
There have been two main hypotheses put forward to explain the multifocal nature of 
urothelial cancers. The concept of field cancerisation first proposed in 1953 by Slaughter et al. 
suggests that the entire urothelium is exposed to a common risk factor putting the entire 
‘field’ of the urothelium at risk of developing tumours (3). These tumours subsequently 
develop independently. Alternatively, a more recent theory of intraluminal ‘seeding’ has been 
proposed. This suggests that cells from a single tumour or lesion can dislodge and implant at 
another site. Molecular studies have supported the ‘seeding’ hypothesis by showing identical 
mutations in tumours from multiple locations (4). A recent review suggests that the seeding 
hypothesis is now well supported but that both mechanisms are likely to occur (2).     
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Two distinct questions can be posed: does the pattern of second urinary cancers support the 
theory of field cancerisation and/or intraluminal seeding? And what factors are predictive of 
the rate of second cancer occurrence within the urinary tract? For the first question in 
particular, the likelihood of a second cancer ‘downstream’ from the kidney can be compared 
with the converse, for instance a bladder cancer followed by kidney cancer, to shed light on 
which mechanism is more likely. NSW Central Cancer registry data provide an opportunity to 
explore the patterns of urinary cancers occurring together at a population level. 
 
Materials and Methods 
All data used were extracted from the NSW Central Cancer Registry. Notifications for invasive 
cancers are mandatory for pathology laboratories, hospitals and other treatment centres 
under the NSW Public Health Act 1991. All first and second invasive cases of cancer for an 
individual were included with third and subsequent cancers excluded from analyses. Two 
analysis techniques were used to address the research questions: the calculation of 
standardized incidence ratios to compare observed versus expected numbers of second 
cancers; and Cox Proportional Hazards regression modelling to investigate predictive factors 
for second cancer occurrence. SAS version 9.2 was used for all statistical analyses.  
Two sets of analyses were undertaken: i) non-bladder urinary cancers as the first cancer sites 
(renal parenchyma, renal pelvis, ureter, and urethra) and bladder cancer as the second cancer 
site;  ii) bladder cancer as the first cancer site and non-bladder urinary cancers as the second 
cancer sites. The first 3 digits of the ICD10 coding system were used to separate organ sites 
with urethra defined at the 4 digit level. Second cancers diagnosed within three months of the 
first cancer were excluded.  
Standardised Incidence Ratios 
A cohort model was used where person-years following diagnosis of the first cancer were 
categorised by single year of age (with an open-ended category from 85 years), sex and 
calendar year of diagnosis. For each analysis, the event was diagnosis of a second primary 
cancer of interest (the target cancer). The follow-up period started at 3 months following first 
diagnosis and was censored at time of death, date of diagnosis of a second primary non-target 
cancer, or 31 December 2007, whichever occurred first. Expected numbers of cases were 
calculated based on the age- and sex-specific incidence rate for each calendar year within the 
follow-up period. Standardised Incidence Ratios (SIRs) were calculated by dividing the 
observed number of second cancers by the expected number of second cancers and 95% 
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confidence intervals were calculated based on the Poisson distribution. The expected number 
of second cancers was based on the incidence of that cancer in the population overall. 
All persons diagnosed from 1986 to 2007 with an invasive upper urinary tract cancer (Renal 
Pelvis: ICD10 code C65 and Ureter ICD10 C66) as a first cancer were included in the cohort. 
Cases without histological verification at the NSWCCR were excluded. An event was the 
occurrence of a histologically verified invasive bladder cancer (ICD10 C67) as a second cancer 
at least 3 months following diagnosis of the first cancer. Individuals were censored at death, 
diagnosis of a non-bladder cancer or 31
Cox Proportional Hazards Regression 
st
Covariates included sex of individual and characteristics of the first cancer diagnosis: age at 
diagnosis (in years); period of diagnosis (in 4-yearly groups); degree of spread of first cancer at 
diagnosis (localised; regionalised; distant and unknown); site of first cancer (renal pelvis vs 
ureter); histology of first cancer (papillary TCC (81303, 81313) vs TCC (81203, 81223)); socio-
economic status at diagnosis (approximated using the index of relative advantage and 
disadvantage based on postcode of residence at time of diagnosis). Proportionality of Hazards 
was assessed by including time dependent forms of each covariate in the model. A full model 
was initially tested with all covariates included as predictors of time to event. A final reduced 
model was constructed by removing non-significant predictors in a step-wise fashion until all 
variables remaining were significant at P<0.05 level.  
 Dec 2007 whichever occurred first. Due to a low 
number of events in non-transitional cell cancers, the cohort was further restricted to include 
only Transitional Cell Carcinoma (TCC, histology codes 81203, 81313, 81303, 81223). The 
cohort comprised 1,700 cases. It should be noted that the inclusion criteria for the Cox 
regression cohort was much stricter than that used in the SIR analysis, focussing on a shorter 
time period (starting at 1986 rather than 1972) and a more specifically defined group (only TCC 
that had been histologically verified). Follow-up began at time of diagnosis of first cancer 
 
Results 
Table 1 presents observed and expected numbers of second cancers by sites of first and 
second cancer and sex. With the exception of bladder cancers following cancers of the renal 
parenchyma for men, all standardized incidence ratios (SIRs) were significant. No bladder 
cancers were observed following cancers of the urethra for women. The largest SIRs observed 
Standardised Incidence Ratios 
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were for bladder cancer following cancers of the renal pelvis (63.8; 95% CI: 52.3-77.1) and 
ureter (80.1; 95% CI: 56.1-111) for women, and urethral cancer following bladder cancer for 
men (58.3; 95% CI: 38.7-84.2).  
For bladder cancers following non-bladder urinary cancers, SIRs were larger for papillary TCC 
compared to TCC. SIRs trended downwards over time with the SIRs for bladder cancer 
following Papillary TCC remaining significant for both males and females at more than 10 years 
of follow-up whereas for bladder following TCC, SIRs at 10+ years dropped to non-significance 
(Table 2).  
All SIRs for combinations of cancers in which the second cancer could be considered 
‘downstream’ of the first were larger than for the corresponding ‘upstream’ combination of 
cancers excepting for cancer of the renal parenchyma. Non-overlapping confidence intervals 
for upstream compared to downstream combinations demonstrate the significance of this 
relationship with the exception of bladder/urethra for women related to the very low numbers 
of urethral cancers in females.  
1,700 patients were included in the cohort with a median follow-up after diagnosis of an upper 
urinary tract cancer as a first cancer of 1.8 years. There was a slight over-representation of 
females, more renal pelvic cancer cases than ureter and most cases had either localised or 
regionalised spread at time of diagnosis. Of the 1,700 patients, 137 (8.0%) developed an 
invasive bladder cancer as a second cancer with a median time to second cancer development 
within this group of 1.0 year.  
Cox Proportional Hazards Regression 
Of the seven variables investigated as predictors of time to bladder cancer, age group, tumour 
site and histological sub-type were significant at the univariate level (Table 3). Those with 
cancer of the renal pelvis developed bladder cancer at a lower rate than those with cancer of 
the ureter (HR=0.65, p=0.02), and those diagnosed with a papillary TCC (histology code 81303, 
81313) were more likely to develop a cancer of the bladder compared to those with TCC 
(histology code 81203, 81223) (HR=1.58, p=0.01). Those in the two oldest age groups were 
more likely to develop bladder cancers compared to those in the youngest age group 
(HR=1.88, p<0.01).  
At a multivariate level, after controlling for all other factors, age group at first cancer diagnosis, 
tumour site and histological sub-type remained as significant as predictors. Results from the 
full model are presented in Table 4 and results from the reduced final model are presented in 
Table 5.  Based on the final model, those aged 65-74 years at diagnosis experienced second 
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cancers at almost double the rate of those younger than 65 years (HR=1.91). Those aged 75+ 
years had  a 68% increased rate of second cancers compared to the < 65 age group. The 
difference between the 65-74 year group and 75+ group was not significant (p=0.36). Initial 
cancers of the renal pelvis were followed by second bladder cancers at only two thirds the rate 
of initial ureter cancer. Initial cancers classified as Papillary Transitional Cell Carcinomas 
(histology code 81303) had a 59% higher rate of second bladder cancers compared to initial 
cancers classified as Transitional Cell Carcinoma (histology code 81203). 
The overall test for non-proportionality of hazards was non-significant (Wald 𝜒𝜒2=3.25, p=0.52). 
Table 1: Observed and expected numbers of second cancers: kidney, renal pelvis, ureter and 
urethral cancers following bladder, and bladder cancers following kidney, renal pelvis, ureter 
and urethra; by sex, 1972-2007 
Sex First Cancer 
Person 
years of 
observati
on 
Second 
cancer 
Observed 
number of 
second 
cancers 
Expected 
number 
of second  
cancers* SIR 95% CI 
Second 
cancer up 
or down-
stream 
 
Male 
Renal 
Parenchyma 
102,991 
Bladder 
 
21 22.5 0.93 (0.58-1.43) Down 
 
Renal Pelvis 11,876 79 3.8 21.0 (16.6-26.1) Down 
Ureter 5,612 35 1.9 18.7 (13.1-26.1) Down 
Urethra 863 3 0.2 13.2 (2.70-38.4) Up 
 
 
      
Bladder 
 
245,315 
Renal 
Parenchyma 
56 41.1 1.36 (1.03-1.77) Up 
Renal Pelvis 71 5.6 12.6 (9.80-15.9) Up 
Ureter 46 2.5 18.4 (13.4-24.5) Up 
Urethra 28 0.5 58.3 (38.7-84.2) Down 
  
 
      
Female
  
Renal 
Parenchyma 
66,348 
Bladder 
 
11 5.1 2.14 (1.07-3.83) Down 
Renal Pelvis 16,222 107 1.7 63.8 (52.3-77.1) Down 
Ureter 3,682 36 0.4 80.1 (56.1-111) Down 
Urethra 287 - 0.0 - - Up 
 
 
      
Bladder 
 
88,796 
Renal 
Parenchyma 
24 8.9 2.71 (1.74-4.03) Up 
Renal Pelvis 34 3.0 11.4 (7.90-16.0) Up 
Ureter 26 0.7 37.1 (24.2-54.4) Up 
Urethra 3 0.1 39.4 (8.10-115) Down 
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Table 2: SIRs by time period following diagnosis and overall for non-bladder urinary as first 
and bladder as second cancer; by histology of first cancer and sex 
 (3mo-<5yrs) (5-<10yrs) (10+ yrs) (overall) 
First Cancer SIR 95%CI SIR 95%CI SIR 95%CI SIR 95%CI 
Female 
        
Papillary TCC 
(8130/3) 
136 (105, 174) 26.6 (10.7, 54.8) 22.2 (8.9, 45.8) 74.3 (58.7, 92.7) 
TCC (8120/3) 113 (85.1, 146) 23.7 (7.7, 55.4) 2.90 (0.10,16.1) 58.8 (45.1, 75.4) 
ALL TCC 124 (103, 148) 25.3 (13.1, 44.2) 12.1 (5.2, 23.8) 66.6 (56.0, 78.5) 
 
        
Male 
        
Papillary TCC 
(8130/3) 
52.5 (40.1, 60.0) 10.6 (3.88, 23.0) 7.70 (2.8, 16.8) 22.6 (22.6, 36.4) 
TCC (8120/3) 26.0 (18.2, 35.9) 7.80 (2.87, 17.0) 1.00 (0.0, 5.40) 9.74 (9.70, 18.1) 
ALL TCC 38.0 (30.7, 46.3) 9.00 (4.65, 15.7) 3.80 (1.60,7.90) 16.7 (16.7, 24.3) 
 
Table 3: Demographic and clinical characteristics of first upper urinary tract cancer diagnosis 
and univariate relationship of covariates to second bladder cancer diagnosis 
Variable Number of observations Unadjusted Hazard 
Ratio (95% CI) 
P value (Log-rank 
Test) 
N %   
Age     
 <65yrs 481 28.3 - 
0.03*  65-74yrs 645 37.9 1.95 (1.26, 3.02) 
 75+yrs 574 33.8 1.79 (1.11, 2.89) 
Sex     
 Male 691 40.6 - 
1.00 
 Female 1009 59.4 1.00 (0.71, 1.41) 
Tumour Site     
 Renal Pelvis 1305 76.8 - 
0.02 
 Ureter 395 23.2 0.65 (0.46, 0.94) 
Degree of spread     
 Localised 737 43.4 - 
0.37 
 Regionalised 644 37.9 0.67 (0.21, 2.14) 
 Distant 162 9.5 0.88 (0.59, 1.30) 
 Unknown 157 9.2 1.40 (0.85, 2.32) 
Histological Sub-type     
 TCC 937 55.1 - 
0.01 
 Papillary TCC 763 44.9 1.58 (1.11, 2.24) 
Period of Diagnosis     
 1986-1989 305 17.9 - 
0.19* 
 1990-1994 373 21.9 1.39 (0.79,2.44) 
 1995-1998 337 19.8 1.89 (1.08, 3.29) 
 1999-2003 393 23.1 1.50 (0.85, 2.66) 
 2004-2007 292 17.2 1.14 (0.56, 2.32) 
IRSAD quintile     
 Lowest 213 12.5 - 
0.39* 
 Second 269 15.8 1.79 (0.92, 3.47) 
 Third 477 28.1 1.40 (0.75, 2.62) 
 Fourth 374 22.0 1.35 (0.70, 2.57) 
 Highest 360 21.2 1.13 (0.57, 2.23) 
 Missing 7 0.4 - 
*indicates a log-rank test for trend, all other values based on log-rank test for difference 
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Table 4: Cox Proportional Hazards Regression – Full Model: Time from upper urinary tract 
TCC diagnosis to diagnosis of bladder cancer as a second cancer– sex, age, site of first 
primary, period of diagnosis, degree of spread, histology, socioeconomic status as predictors  
Definition of Model: 
Cohort All persons with a diagnosis of the ureter or renal pelvis who survived at least 1 day and 
were diagnosed using method 6 (histological verification at CCR) 
Entry Date of diagnosis of upper urinary tract TCC 
Event Diagnosis of bladder cancer occurring >=3 months post first cancer diagnosis 
Censoring Diagnosis of non-bladder cancer, death or 31st
Variable 
 Dec 2007 whichever occurred first 
Categories  Hazard Ratio (95%CI) P(Wald) 
      
Site Ureter  1.00  
0.03 
 Renal Pelvis  0.66 (0.46, 0.96) 
      
Sex M  1.00  
0.84 
 F  1.02 (0.68, 1.37) 
      
Year of diagnosis 1986-1989  1.00  
0.27 
(ydg) 1990-1994  1.32 (0.75, 2.32) 
 1995-1998  1.69 (0.96, 2.97) 
 1999-2003  1.26 (0.71, 2.24) 
 2004-2007  0.92 (0.44, 1.89) 
      
Degree of spread at 
diagnosis 
Localised  
1.00  
0.76 (stage) Regionalised  0.94 (0.63, 1.40) 
 Distant  0.81 (0.25, 2.61) 
 Unknown  1.25 (0.75, 2.09) 
      
Histology TCC  1.00  
0.01 
(hist) Papillary TCC  1.60 (1.12, 2.29) 
      
Age <65yrs  1.00  
0.01 (age) 65-74yrs  1.95 (1.25, 3.05) 
 75+ yrs  1.85 (1.12, 3.04) 
      
IRSAD quintile Lowest  1.00  
0.30 
 Second  1.74 (0.90, 3.37) 
 Third  1.36 (0.73, 2.54) 
 Fourth  1.26 (0.66, 2.41) 
 Highest  1.00 (0.50, 1.98) 
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Table 5: Cox Proportional Hazards Regression – Reduced Model: Time from upper urinary 
tract TCC diagnosis to diagnosis of bladder cancer as a second cancer– age, site of first 
primary, degree of spread, histology 
Definition of Model: 
Cohort All persons with a diagnosis of the ureter or renal pelvis who survived at least 1 day and 
were diagnosed using method 6 (histological verification at CCR) 
Entry Date of diagnosis of upper urinary tract TCC 
Event Diagnosis of bladder cancer occurring >=3 months post first cancer diagnosis 
Censoring Diagnosis of non-bladder cancer, death or 31st
Variable 
 Dec 2007 whichever occurred first 
Categories  Hazard Ratio (95%CI) P(Wald) 
      
Site Ureter  1.00  
0.02 
 Renal Pelvis  0.66 (0.46, 0.94) 
      
Histology TCC  1.00  
<0.01 
(hist) Papillary TCC  1.59 (1.12, 2.24) 
      
Age <65yrs  1.00  
0.01 (age) 65-74yrs  1.91 (1.24, 2.95) 
 75+ yrs  1.68 (1.04, 2.69) 
      
 
 
Discussion 
The present study examined the elevated risk of experiencing a second invasive cancer 
diagnosis within specific sites of the urinary tract following an initial invasive urinary cancer. It 
also explored several potential factors that may elevate risk in the specific example of bladder 
cancer following cancer of the upper urinary tract.  
There was a clear elevation of risk of bladder cancer following cancers of the renal pelvis and 
ureter in both males and females. This contrasted with less clear findings for bladder cancer 
following cancer of the renal parenchyma (with significantly elevated risk for females but not 
males) and of the urethra (with elevated risk for males, but indeterminate risk for females due 
to no observed second cancers). The differences between males and females in terms of 
standardised incidence ratios for second urinary cancers, reflects an underlying difference in 
incidence patterns between cancers of the upper urinary tract and cancers of the bladder, with 
most bladder cancers in NSW diagnosed in men, but a more even distribution of renal pelvis 
and ureter cancers between the sexes. This suggests a difference in causal factors between the 
two sites. McCredie et al. postulated that this could reflect underlying differences between the 
sexes in exposure to phenacetin containing analgesics which were removed from the market in 
the 1980’s. (1).  
When examining the reverse relationships, risks of renal parenchyma, renal pelvis, ureter and 
urethra cancers were all elevated following initial bladder cancer diagnosis for both males and 
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females. However, for all cancer sites that comprise the urothelium (including the renal pelvis, 
ureter, bladder and urethra), risks were highest when the second cancer was ‘downstream’ of 
the first. For example, risk of bladder cancer following renal pelvis was significantly higher than 
renal pelvis following bladder and risk of urethra cancers following bladder was significantly 
higher than bladder following urethra. However, this relationship did not hold for cancers of 
the renal parenchyma.  
At the time of reporting, McCredie et al. did not examine the increased risk of renal cancers 
following invasive bladder cancer. It would be expected that field cancerisation caused by 
exposure to a common etiological factor would increase the risk of cancer across the entire 
urothelium. This theory does not propose a reason why cancer might develop more rapidly in 
one area of the urothelium compared to another, suggesting an equally elevated risk of renal 
pelvis cancer following invasive bladder cancer compared to the reverse relationship. 
Alternatively intraluminal seeding suggests a mechanical action of spread by which cancer cells 
move within the urinary tract and ‘seed’ to another area. It would be expected that the risk of 
cancers occurring ‘downstream’ of a first cancer would be greater than the risk of second 
cancers in ‘upstream’ sites due to the directional flow of urine. 
This pattern of excess risk supports the theory that second cancers of the urothelial tract may 
manifest due to a ‘seeding’ of cells from a prior cancer, assisted by the flow of urine. The 
influence of urinary flow in transporting cancerous cells is also supported by findings that 
patients who experienced urinary ‘reflux’ from the bladder to the ureter were more likely to 
develop cancers in the upper urinary tract (5). However, the significantly elevated risks for 
second cancers that were located upstream of the first also suggests that other mechanisms 
such as field cancerisation are important.  
Several studies have examined risk factors for the occurrence of second cancers in the urinary 
tract, but most have been retrospective examinations of case series or small cohort studies 
within single institutions.  Commonly cited factors predictive of bladder tumours following 
cancer of the upper urinary tract include tumour grade, multifocality, location (ureteric 
tumours having higher risk of recurrence than renal pelvic) and surgical procedure, with other 
factors such as sex and tumour size reported only on occasion (6) (7) (8) (9). Fewer studies 
have examined the risk of upper urinary tract cancers following bladder cancer, although one 
population-based analysis using data from the SEER database in the US found that tumour 
grade, stage and location were predictive of upper urinary tract recurrence (10).  
As well as site of initial cancer, both the examination of SIRs and survival modelling 
demonstrated initial cancer histology as an important predictor of second cancer occurrence. 
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Those diagnosed with an initial papillary transitional cell carcinoma were more likely to 
develop a second bladder cancer than those diagnosed with a transitional cell carcinoma not 
otherwise specified. This is the first study that the author could locate that has examined 
histological sub-type as a predictor of a second urinary tract cancer.  
Risk factors for bladder cancer in the general population would also be expected to be risk 
factors for second bladder cancers. Age at diagnosis was a positive predictor of second bladder 
cancer occurrence after controlling for other factors. As urothelial cancer incidence is rare 
under the age of 60, it is unsurprising that the risk of second bladder cancers increases with 
age. However, sex is also generally a risk factor for bladder cancer, with males more likely to 
be diagnosed than females, but sex was not significant in predicting second bladder cancers 
following cancers of the transitional cell carcinomas of the upper urinary tract. Factors such as 
smoking rates and to a lesser extent workplace exposure to aromatic amines are thought to 
increase the risk of bladder cancer for males, and are also risks for urothelial cancers in 
general. It seems likely that those diagnosed with an upper urinary tract cancer had a more 
equal distribution between the sexes of known bladder cancer risk factors than the population 
in general. Due to the high level of censoring due to death in some sub-groups in this study 
(such as the elderly) it is may be beneficial to re-examine the relationship of covariates using a 
competing risk model which will allow a more sophisticated inclusion of death within the 
model. 
There are limitations in the registration practices of urinary cancers that need to be considered 
in the context of this study. Errors in the identification and coding of invasive versus non-
invasive bladder cancers have been previously documented including within the SEER program 
and the NSW Central Cancer Registry (11) (12).  Due to the variability over time in the coding of 
invasive versus in situ cancers, the SEER program has routinely reported incidence inclusive of 
both invasive and in situ to avoid what would otherwise result in an artefactual decrease for 
invasive cancers and increase for in situ cancers over time as coding practices were improved 
(11). Within NSW the reporting of in situ cancers is not mandatory, but following internal 
review of notifications many cancers have been recoded from invasive to in situ. A review in 
2008 suggested that as many as 30% of transitional cell carcinomas and 70% of papillary 
transitional cell carcinomas were no longer classified as invasive following pathological 
verification (12). From 2006 onwards, bladder cancer registrations within the NSW CCR data 
were made more consistent, with all localised or unknown cancer registrations histologically 
verified. 
22 
 
In situ cancers and non-invasive low grade papillary carcinomas have been speculated to 
follow separate mutational pathways but both potentially leading to invasive cancers (2). As 
reporting of in situ urothelial cancers to the NSW Cancer registry is not compulsory, it is 
difficult to include in situ cases in any analyses due to the unknown coverage of this type of 
cancer. The present study was limited to invasive cancers which were histologically verified 
within the NSW Central Cancer Registry.  It should be noted that this will have excluded a 
proportion of potentially eligible cases. Exclusion of both non-invasive cancers and non-
verified invasive cancers is likely to reduce the power of any analysis, but is only likely to bias 
the results if exclusion of these cancers is related to the location of the tumour or the other 
covariates of interest.  
Previous studies have found cancer stage to be a significant predictor of urothelial cancer 
recurrence with Carcinoma in Situ (CIS) to be associated with more frequent occurrence of 
subsequent cancers (8). The present study excluded all CIS and therefore had no scope to 
examine this relationship. When examining the order of cancer occurrence between different 
sites in the urothelial tract, it is important to recognize that a first cancer may have been 
preceded by a non-invasive cancer in another location. This may bias the results if non-invasive 
cancers are related to site of cancer. Additionally non-verified registrations may be linked to 
other factors such as year of diagnosis and the exclusion of these cases may interfere with the 
ability to examine this as a predictor of second cancer occurrence.  
The elevated risk of bladder cancer following cancer of the renal pelvis and ureter clearly 
reflects the multifocal nature of urothelial tumors, and in 2004 it was proposed that rules for 
reporting ‘second primary cancers’ from cancer registries be adjusted to count the entire 
urothelium including the renal pelvis, ureter, bladder and urethra as one organ site (13). Thus, 
a second cancer occurring in any of these organs of the same histological group would be 
counted as a multiple cancer rather than as a second primary cancer and therefore excluded 
from incidence and mortality statistics. Previously, the renal pelvis and ureter were included 
with the renal parenchyma as one organ site and bladder was a treated as a separate organ 
site. 
Further analysis using registry data from other jurisdictions such as the SEER database in the 
USA is warranted to validate the findings here and extend the study to include non-invasive 
cancers. This study also underlines the complex and recurring nature of cancer diagnoses in 
the urothelial tract and the importance of accurate histological coding in cancer registries.  
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Appendix: Overview of Statistical Analyses 
 
A1  Data Management 
Three datasets were utilised for this study: 
• The NSW Central Cancer Registry (CCR) reporting dataset accessed via the Cancer 
Institute NSW which included all registrations of invasive cancers in NSW from 1972 to 
2007, linked to death information from the national death index.  
• ABS resident population estimates for NSW for the years 1972 to 2007, accessed via 
the NSW Health Outcomes Statistical Toolkit (HOIST). 
• Indices of Relative Socioeconomic Advantage and Disadvantage (IRSAD) for NSW 2006 
(by postcode), accessed via the ABS.  
The NSW CCR reporting dataset was made accessible through my secondment to the 
Monitoring, Evaluation and Research Unit at the Cancer Institute NSW for the purposes of the 
project.   
The Estimated Resident Population for NSW by sex and single year of age (grouped for 85+) 
was used in the first analyses to calculate expected numbers of second cancers. The IRSAD 
indices were linked to the CCR dataset based on postcode of residence at time of diagnosis.  
For both parts of this project the CCR dataset required transforming to link first and second 
cancer diagnoses for an individual based on the order of date of diagnosis. Third and later 
cancers were excluded for the purposes of this project.  
The CCR variables used included: 
• Registration number (to enable linking of first and second cancers) 
Person level characteristics 
• Sex (covariate of interest) 
• Month of death (to allow for censoring at time of death, day was set at “15”) 
• Year of death (to allow for censoring at time of death) 
• Age at diagnosis (covariate of interest) 
First cancer diagnosis characteristics 
• Month of diagnosis (to allow calculation of date of entry to a cohort. Day was set at 
the “15th” of the month)  
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• Year of diagnosis (date of entry) (covariate of interest) 
• Site of tumour (ICD-10 coding at a four digit level) (covariate of interest) 
• Histology of cancer (ICD-03 coding at a four digit level) (covariate of interest) 
• Method of diagnosis (to allow selection of cases where histology sighted at CCR 
(Method=6)) 
• Stage at diagnosis (highest degree of spread of cancer within 4 months of diagnosis 
(1=localised; 2=regionalised; 3=distant; 9=unknown)) (covariate of interest) 
• Postcode of residence at time of diagnosis (to allow linkage to IRSAD index) (covariate 
of interest) 
• Month of diagnosis (to allow calculation of date of event. Day was set at “15
Characteristics of second cancer diagnosis 
th
• Year of diagnosis (date of event)  
” of each 
month)  
• Tumour site (to allow selection of events of interest) 
• Tumour histology (to allow selection of events of interest) 
• Method of diagnosis (to allow selection of events of interest) 
 
A2:  Evaluating excess risk of other urinary tract cancers following an initial urinary tract 
cancer diagnosis 
Primary: To explore estimates of the elevated risk of second urinary cancers of different organ 
sites following an initial urinary cancer diagnosis.  
Aim of the analysis: 
Secondary: To explore patterns of excess risk based on site of first cancer, histology of first 
cancer and sex 
Selection and definition of cancer sites  
Rationale for the approach taken: 
Distinct urinary organs were split into non-bladder and bladder for pragmatic reasons. Non-
bladder urinary cancers included: Renal Parenchmya (main body of the kidney); Renal Pelvis 
(neck of the kidney that adjoins the Ureter); Ureter (joining the renal pelvis to the bladder); 
and Urethra. Due to coding rules, second primary cancers of the same organ site are excluded 
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from the CCR reporting database. In the case of urinary cancers, non-bladder cancers have 
historically been classed as the same organ site and bladder cancers as a separate organ site. 
This classification has changed since 2004 to include Renal Pelvis, Ureter and Urethra with 
Bladder and Renal Parenchyma as a separate organ site. Coding rules within the CCR have 
remained the same with reporting allowing for the change in rules. These historic rules allow 
examination of relationships between second primary bladder cancers following primary non-
bladder cancers and vice versa, but do not allow investigation of multiple primary cancers of 
different sites within the non-bladder cancer group.  
Calculation of Standardised Incidence Ratios (SIRs) 
SIRs were calculated to allow investigation of rates of cancers within the population of interest 
(those diagnosed with an initial primary cancer of specific type) compared to the ‘healthy’ 
population (those not diagnosed with an initial primary cancer). The retrospective cohort 
approach is a commonly used epidemiological approach to calculate the number of observed 
versus expected cases required in the calculation of SIRs. This approach has also been the 
focus of previous work within the Cancer Institute NSW to develop a standard SAS program 
that can be adapted to explore second cancer occurrence for cancer types of interest.  
The existing SAS program allowed flexible investigation of different combinations of cancers. 
This program operates by the following steps: 
Existing SAS program to calculate SIRs: 
1. CCR data is read in (using the re-shaped dataset with only first and second diagnosis 
and using all diagnoses from 1972 to 2007)  
2. NSW population counts by age, sex and calendar year are downloaded for the period 
1972-2007 
3. Three cohorts are created based on the specification of the initial cancer of interest 
and sex: 
• Cohort C:  >2 months post entry date to study end date; 
• Cohort B:  >2 to 119 months; and 
• Cohort A:  >2 to 59 months 
Where study entry date is the date of diagnosis of a person’s first cancer diagnosis. A person 
enters the cohort on this date and contributes person years of observation until diagnosis of a 
second cancer, death or study end (31 December 2007).  
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The construction of three separate cohorts allows calculation of SIRs for three distinct time 
periods, 3mo-<5yrs (cohort A), 5yrs-<10yrs (Cohort B-Cohort A) and 10 yrs plus (Cohort C-
Cohort B) as well as an overall SIR (Cohort C). Diagnoses of second cancers made within the 
first three months were excluded to allow for multiple ‘synchronous’ diagnoses in which the 
order of occurrence may be uncertain. 
4. Observed cases of each cancer type within each cohort are counted for each stratum 
(stratified by age last birthday, sex and calendar year of diagnosis). 
5. Population incidence of each cancer type is calculated within each cohort for each 
stratum 
6. Person years of observation are calculated within each cohort for each stratum 
7. Expected cases of each cancer type are calculated within each cohort for each stratum: 
 Expectedstratum = Incidencepopulation ∗ pyo stratumpy opopulation  
8. SIRs are calculated in each cohort:  
 SIRcohort = ∑ Observe dcohortstrata∑ Expecte dcohortstrata  
9. 95% confidence intervals are constructed based on the Poisson distribution.  
 
The existing SAS program could be used to calculate SIRs for each of 54 programmed second 
cancer types for the specified initial cancer type and results could be output either individually 
for each sex or combined. Slight modification of the program was required to disaggregate the 
grouping of “Kidney” for definition of second cancer type which initially included all non-
bladder urinary sites of Renal Parenchyma, Renal Pelvis, Ureter, Urethra and other urinary 
organs not otherwise specified. These were re-defined as separate cancer types.  
Adapting the existing SAS program: 
Additional factors such as histology were also included in the definition of initial cancer type to 
allow more specific investigations to be carried out.  
One of the main potential limitations of the SAS algorithm used is the issue of interpreting 
multiple comparisons. With a large number of combinations of cancers able to be investigated 
Potential limitations of this approach 
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and then also broken down into sub-groups such as by sex and histology, it would be expected 
that a number of ‘significant’ findings in such a large number of comparisons could occur by 
chance alone. However, in the present study the number of analyses were limited and based 
on a priori hypotheses which reduce the significance of this issue.  
 
A3:  Determining predictors of second cancer occurrence through Cox Proportional 
Hazards regression modelling 
To determine what factors predict the occurrence of an invasive bladder cancer following an 
upper urinary tract cancer. 
Aim of the analysis:  
Survival analysis was considered an appropriate technique for examining predictors of second 
cancer occurrence. The main reason for this was that the ability to observe the occurrence of a 
second cancer could be highly biased due to censoring when a person dies. As cancers can 
have quite high death rates, and most covariates of interest could potentially be related to 
death rates, the impact of censoring could be significant. It was possible for one person to be 
diagnosed with many cancers. So as to allow examination of the relationship between just two 
cancers of interest, a person was considered censored at the date of a non-bladder cancer. 
Survival analysis provides more information on the rate of cancer occurrence over time that 
could not be gained by just examining SIRs.  
Rationale for the approach taken: 
The potential issue with this approach given the dataset included the possibility of missing 
data due to loss of follow-up when people move interstate or overseas. However, due to the 
co-operation between jurisdictions within Australia and the efforts made in matching death 
records, this issue is likely to have minimal effect.  
Another issue is that a high proportion of cases of first cancers in older age groups will have 
died before having the chance to acquire the second cancer. As there are differences in death 
rates at different levels of covariate, it may be misleading to regard deaths as the same as 
censored observations. Accordingly, proportional hazards regression incorporating competing 
causes/risk is likely to be a more appropriate approach. It is the intention that this method of 
analysis will be undertaken over the coming months to increase to validity of the findings 
before further considering this paper for publication. 
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SAS Version 9.2 was used for all analyses. SAS is the standard statistical analysis software 
supported within the Cancer Institute NSW and also allows for analysis of large datasets.  
 
a) Assessing the distribution of each variable 
Overview of the analysis steps taken: 
Each variable was inspected for outliers and distribution was assessed.  
There were 1700 observations with a valid time to event (>0.0yrs). Time to event was highly 
right skewed which is not unusual for this type of data, but the nature of the administrative 
dataset allows a very long follow-up period resulting in a large range of values from 0.04-21.8 
years with a median follow-up time of 1.8 years. 
Two covariates could potentially be included in the analysis as continuous variables: age and 
year of diagnosis (ydg). Histograms for these two variables are presented in Figure A1. Year of 
diagnosis, as expected had a fairly flat distribution and as there was no prior reason to assume 
that this variable would be linearly related to the occurrence of bladder cancer, it was treated 
instead as a categorical variable labelled “period of diagnosis” with 4-5 yearly groupings. Age 
appeared to be reasonably normally distributed with a slight tail to the left. Based solely on the 
distribution, it did not appear necessary to transform this variable and it was included in the 
continuous form for further investigation of the survivorship function by different levels of the 
covariates.   
An overview of the proportional distribution of categorical variables across groups was 
presented in table 3 on page 18.  No significant issues were identified.  
 
b) Assessing the overall survivorship function 
The Kaplan-Meier survival curve was calculated (Figure A2). This showed that the overall 
proportion of the cohort experiencing the event of interest (diagnosis of a bladder cancer) was 
quite low and that the rate of second cancers was fastest in the first 2.5 years following initial 
cancer.  
 
c) Assessing the survivorship function by each level of each covariate 
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Kaplan-Meier survival curves were examined for each level of covariate to examine potential 
predictors and log(-log) survivor functions were plotted against log survival time to help 
identify any potential issues with assuming proportionality of hazards (Figures A3). The only 
covariates that appeared to be clearly related to time to second cancer at the univariate level 
were age, site of first cancer and histology. A log-rank test confirmed these relationships to be 
significant (Table 3 on page 18). Year of Diagnosis (grouped into five periods) appeared not to 
be strongly related to second cancer occurrence and there was no uniform increasing or 
decreasing trend across periods. The lack of trend was supported by a non-significant log-rank 
test for trend (p=0.51). Age did appear to be related to time to second cancer with a significant 
log-rank test for trend (p=0.03). However, the trend did not appear linear with the oldest two 
age groups appearing to have similar survivorship. There was also an indication that hazards 
may not be proportional at all survival times for age. Based on these findings, and to aid in 
simplicity of interpretation, the decision was made to include age as a categorical variable and 
test the proportional hazards assumption further at a multivariate level.   
 
d) Building the Cox Proportional Hazards Model 
All potential covariates were initially included in the model. This “full” main effects model 
showed a significant effect of site, histology and age group on time to second cancer. All other 
covariates were non-significant at the 5% level. As the main purpose of the analysis was testing 
the significance of potential predictors, the full model was of interest and the results reported.  
However, a more parsimonious main effects model was also investigated. Covariates were 
removed from the full model one by one based on descending p values until only significant 
predictors remained. No further covariates became significant and the reduced model 
remained with three covariates site, histology and age group. There are some limitations in 
constructing a regression model in this way. For example, confidence intervals for effects may 
be overly narrow. However, both the full and reduced model are reported and effects for the 
three significant predictors remained reasonably consistent. 
Interaction effects were also investigated within this reduced model. There was no prior 
clinical rationale for examining particular interaction effects. However, it was possible that the 
effect of histology could vary by site and also that the effects of both histology and site could 
vary by age. Five interaction terms were constructed by creating dummy variables (Age_65-
74*HistTCC, Age_65-74*SiteRenalPelvis, Age_75+*HistTCC, Age_75+*SiteRenalPelvis, HistTCC 
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*Site_RenalPelvis) and were included individually one by one in the reduced main effects 
model. None were significant at the 5% level and so were not included in the model.  
 
e) Model Diagnostics 
(i) Assessing the Proportional Hazards assumption 
Schoenfeld residuals were used to assess the assumption of proportional hazards for each 
covariate in the reduced main effects model. The advantage of examining Schoenfeld residuals 
is that it allows examination of which covariates may be violating the proportional hazards 
assumption. Residuals were plotted against survival time (Figure A4). There were some slight 
deviations at low and high survival times for all covariates.  To further investigate this issue, 
time-dependent versions of the covariates were included in the model by including covariate 
by time interaction terms. None of the time-dependent interaction terms were significant at 
the 5% level and the overall test of non-proportionality was non-significant (Wald 𝜒𝜒2=3.25, 
p=0.52). This provides support for the appropriateness of the Cox model.   
(ii) Assessing overall model fit and influential observations 
Deviance and Martingale residuals were examined to assess overall model fit. Figure A5 shows 
the respective residuals plotted against the linear predictor. There was no overall skew 
towards high or low values of the linear predictor. However, there did appear to be a number 
of observations with very high positive residuals. Further examination of the deviance 
residuals plotted in conjunction with LMAX values (Figure A6- high LMAX values indicated by 
larger diameter circles) suggested that there were a number of observations with high 
influence and high positive residuals. Observations with residuals higher than 2.5 were 
inspected, but no obvious data errors existed. These were all observations that experienced 
the event of interest, had very short survival times and included a mix of covariate values. 
Removing the highest 5 values (with deviance >3) did not make any significant difference to 
covariate estimates.   
Overall, the residuals appeared to reflect the divergence between censored observations 
which tended to have longer survival times than predicted (negative residuals) and non-
censored which had shorter survival times than predicted by the model (positive residuals). 
This is consistent with a population that experiences a low event rate with most events 
occurring in the first few years but with potentially very long follow-up period for censored 
observations due to the passive nature of surveillance (determined by matching to death 
records rather than active participation).  
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The model explains only a small proportion of variation in time to event. However, there 
appears to be no overall bias for particular covariate values and towards particular survival 
times. Given the main purpose of the analysis was to examine potential covariate predictors 
rather than predict survival times, the model appears appropriate for this purpose.  
 
f) Final Model 
Following assessment of model diagnostics, the reduced main effects model was accepted as 
the most parsimonious model summarising the significant predictors of time to bladder 
cancer.  
 
Figure A1: Histograms - Age at first cancer diagnosis and year of first cancer diagnosis 
 
 
Figure A2: Kaplan-Meier survival curve for reduced main effects model 
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Figure A3: Kaplan-Meier survival curves and log(-log) survivor functions for each covariate 
a) Site of First Cancer 
 
b) Histology 
 
c) Age Group 
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d) Period of Diagnosis 
 
e) Index of Relative Advantage and Disadvantage 
 
f) Sex 
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Figure A4: Schoenfeld Residuals for each predictor 
 
  
 
Figure A5: Martingale and Deviance Residuals for model 
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Figure A6: Deviance Residuals plotted with influence diagnostics (larger diameter circles 
indicating higher LMAX scores). 
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Multiple Imputation to address a data artefact for the degree-of-spread 
variable in the NSW CCR for the period 1993 – 1998: Lung Cancer as a 
test case 
 
Abstract 
An artefact in degree-of-spread coding within the NSW Central Cancer Registry (CCR) data 
occurred for all solid-tumour cancers, excepting breast and melanoma, diagnosed for the 
period 1993-1998 (1). This resulted in a decrease of cases coded as localised and an increase in 
cases coded as unknown. The cause was the introduction of the Electronic Notification System 
(ENS). Cancers with regionalised or distant degree of spread were unaffected. This artefact has 
implications for using the degree of spread variable within the CCR and imposes limitations on 
analyses.  This paper outlines the scope of the problem for one cancer type – lung cancer – and 
investigates multiple imputation (MI) as a method for addressing the problem.  Cases with 
“unknown” degree of spread that included electronic notifications were classified as having 
missing values for the degree of spread variable for the period 1993-1998. Cases were then re-
allocated to the localised and unknown categories based on MI, using a logistic regression 
model as the basis for prediction. The model produced plausible results that appeared to 
correct the artefact and were consistent across sub-groups. Independent validation in a 
distinct time period suggested that the model had reasonable prediction accuracy (69%) for 
coding localised cases. Survival was significantly poorer for localised cases within the period 
1993-1998 based on imputed data compared to original coding, but imputation had no effect 
on survival when degree of spread was unknown. The MI model tested was specific for lung 
cancer but could also be modified and tested on other cancer types affected by the data 
artefact.     
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Section 1: An overview of the problem 
 
Background: The NSW Central Cancer Registry 
The NSW Central Cancer Registry (CCR) receives notifications of all malignant cancers 
diagnosed in NSW. The CCR is managed by the Cancer Institute NSW for the NSW Department 
of Health (NSW Health), and operates under the authority of the Public Health Act of 1991. The 
Registry maintains a record of all malignant cancer cases diagnosed in NSW residents since 
1972. However, notification of malignant neoplasms has been a statutory requirement for all 
notifying institutions in NSW since 1986.  
These institutions include public and private hospitals, departments of radiation oncology, 
nursing homes, pathology laboratories, outpatient departments and day procedure centres. 
When any of these institutions diagnose or treat someone with malignant cancer, they are 
required by law to notify the NSW Central Cancer Registry. Notifications of cancer in NSW 
residents are also received from cancer registries in other states and territories. 
The NSW Central Cancer Registry aims to monitor the number of new cases of cancer and 
deaths from cancer in NSW and assist in cancer prevention and control by producing 
descriptive analyses of cancer incidence and mortality trends, facilitating epidemiological and 
clinical research, and supporting planning, evaluation and monitoring of services and screening 
programs. 
To this end, the NSW CCR reporting database contains a mixture of demographic and clinical 
variables.  It records the year and month of birth, death and diagnosis of each cancer case in 
NSW, plus basic demographic variables such as sex, Aboriginal and Torres Strait Islander status 
and postcode. Clinical variables such as the site of cancer, histology of cancer, method of 
diagnosis and degree of spread are coded by medical coders within the NSW CCR based on 
information provided within notification reports. 
Degree of spread in the NSW CCR is a summary measure based on cancer staging at first 
presentation. It is derived by the CCR from the maximum extent of disease based on all reports 
and notifications dated within four months of the date of diagnosis. Degree of spread reported 
here follows the international coding guidelines for summary stage adopted by several 
international groups including the World Health Organization and the International Association 
of Cancer Registries (2).  
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Degree of spread is grouped as:  
(i) localised (assumed to predominantly consist of TNM Stage 1 but may include some 
Stage 2)  
(ii) regionalised (assumed to be predominantly TNM Stage 2 and most of Stage 3)  
(iii) distant (predominantly TNM Stage 4 cancers).  
(iv) Some cancers are classified as unknown degree of spread for which staging 
information is inadequate or has not been collected.  
 
Background: Data Artefact  
Barraclough et al. described an artefact in NSW Central Cancer Registry (CCR) data that 
occurred for all solid-tumour cancers, excepting breast and melanoma, diagnosed for the 
period 1993-1998 (1). For these cancers within this period, the proportion of ‘localised’ cancer 
cases reported was approximately 5% lower than expected and was mirrored by an artefactual 
increase in ‘unknown’ degree-of-spread cases. This was caused by the introduction of the 
Electronic Notification System (ENS) which only affected the accuracy of coding of localised 
cancers, with regionalised and distant degree-of-spread cancers unaffected. This artefact has 
implications for using the degree of spread variable within the CCR and imposes limitations on 
analyses. 
Figure 1 presents the proportion of lung cancer cases by degree of spread coding category for 
the years 1986-2004 based on year of diagnosis. There was a marked rise in unknown cases 
from 1992 to 1993, mirrored by a drop in localised cases. Lung cancer shows an under-
estimation of localised cases of almost 10 percentage points from what would have been 
expected during this period – much higher than the overall cancer artefact reported by 
Barraclough et al. These trends were caused by the absence of a ‘localised’ category within the 
ENS and were corrected in 1999 when the ENS was amended. This artefact can be even more 
clearly seen when considering just localised and unknown lung cancer cases (figure 2).  
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Figure 1: Percentage of Lung Cancer Cases by Degree of spread at diagnosis – 1986-2004 
 
 
It is possible to ascertain for each diagnosed case, the method(s) of notification received by 
the CCR using the batch number of each notification episode. Multiple notifications may be 
received for a single case, for example from both a hospital and pathology lab. All notifications 
dated within 4 months of diagnosis are used to assess the degree of spread at diagnosis, and 
the case is categorised based on available information. The introduction of electronic 
notifications was a gradual process with almost 100% of lung cancer cases based on manual 
notifications (M) prior to 1993 which then dropped to about 60% by 1994, 45% by 1999 and 
30% in 2004. This was mirrored by a gradual increase in cases notified by electronic means 
only (E) and a less gradual increase in cases notified by a mixture of manual and electronic 
means (EM) (Figure 3). There were a small number of cases diagnosed prior to 1993 that 
included electronic notifications. This is plausible given the possibility of a delay between an 
episode of care (eg. seeing a patient within a hospital) and a notification being sent. 
Additionally, as degree of spread is coded based on notifications within a four month window, 
cases diagnosed at the end of 1992 may have had notification episodes in 1993. 
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Figure 2: Percentage of Unknown and Localised Lung Cancer Cases by Degree of spread at 
diagnosis – 1986-2004 
 
Figure 3: Percentage of Unknown and Localised Lung Cancer Cases, by Method of 
Notification, 1986-2004 
 
 
Examination of trends in the ratio of localised versus unknown degree of spread by year of 
diagnosis (Figure 4), suggests that the known data artefact (evidenced by under reporting of 
‘localised’ cancers and over-reporting of ‘unknown’ cancers) includes cases notified by 
electronic means only (E) and cases where some manual episodes were recorded in addition to 
the electronic episodes (EM). The cause of the artefact was the exclusion of a category for 
‘localised’ cases on the ENS which meant that the notifying party could not select this 
response. For lung cancer, the information required for coding degree of spread was likely to 
have come from either: (i) imaging which would have been noted within hospital reports, or (ii) 
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pathology reports. Electronic notifications during this period would generally have comprised 
hospital reports, mostly from the public sector, with private hospitals commencing electronic 
notification at a much later time. Pathology reports are received manually which means that 
cases diagnosed based only on electronic notifications only would not have included 
pathology.   
The implication of the changeover to ENS was that some information regarding degree of 
spread based on imaging may have been lost if the hospital report was submitted using the 
ENS. However, information gained from pathology reports or from hospital reports not 
submitted via the ENS was still available for coding this category. For the EM-notified cases this 
means that during 1993-1998 there may have been information available to code degree of 
spread if the manual notifications included pathology or private hospital reports, but that once 
the ENS was amended, the information gained from public hospital notifications would have 
been included again, increasing the amount of information available within the EM category.  
For cases notified by electronic means only (E) only a very small proportion of cases were 
coded as localised during this period. In a very small number of situations there may have been 
adequate information provided elsewhere on the electronic notification to code the case.  
Figure 4 shows the clear and rapid increase in proportion localised between 1998 and 1999 for 
both the E and EM groups following the amendment of the ENS. From 1999 onwards, cases 
within the EM group show a much higher proportion of localised cases compared to either the 
E or EM groups. This can be explained by two factors. Firstly, these cases are more likely to 
have both imaging and pathology information which is likely to increase the chance of being 
able to accurately code degree of spread. The manual only group may have pathology but are 
less likely to have information from public hospitals and the electronic only group are less 
likely to have pathology. Secondly, the EM group were most likely to have a diagnosis made 
based on histopathology (including verified by CCR and unverified) rather than other means, 
compared to the E and M groups. Histopathology, particularly if it had been verified within the 
CCR, was a strong predictor of the ability to categorise cases as “localised” compared to 
“unknown” (data presented in section 2 and Appendix A).  
Those cases notified by manual means only (M) show a steady decline in proportion localised 
over time, but do not show evidence of a data artefact for the period 1993-1998. The decline 
in proportion localised must have been driven by non-ENS related factors prior to 1993, but 
following 1993 may also be explained by a proportion of cases ‘shifting’ into the electronic plus 
manual category. Within this category it is more likely that multiple notification episodes 
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occurred and a clear link was found between number of notification episodes received and the 
ability to categorise the cancer as “localised” (data presented in section 2 and Appendix A).   
 
Figure 4: Proportion of Localised cases (of all localised and unknown) by method of 
notification, 1986-2004 
 
 
These figures support the finding that the data artefact is linked to the introduction of the ENS 
in 1993, with manual cases unaffected during the period 1993-1998. Additionally it appears 
that cases were affected even if notifications were received manually and electronically (EM) 
rather than just by electronic means only (E).  
 
Missing data 
The proposed approach to dealing with this data artefact relies on the assumption that we can 
justify classifying the problematic data as ‘missing’. Missing data are the result of a ‘missing 
value mechanism’, which may not be clearly identified. In the case of surveys, and 
administrative health information, data can be missing for 6 generic reasons:  
(i) the question may not have been asked of a respondent or patient;  
(ii) the question was asked but the subject did not respond for various reasons including 
refusal or ‘no comment’;  
(iii) the question was asked and the respondent did not know the answer but there was no 
‘not known’ response category in the data collection instrument or database;  
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(iv) the question was asked and the respondent responded but for some reason the 
response was not recorded;  
(v) the question was asked, the respondent answered, the response was recorded but the 
data were not entered;  
(vi) the data are missing legitimately, as in a ‘not applicable’ response, but this category 
may not be in the data collection instrument or database.  
 
Missing data can cause problems with analyses by reducing statistical power and potentially 
introducing bias into estimates (3). If data are missing completely at random (MCAR), the cases 
with missing data are akin to a random sample of the observed cases.   While this may reduce 
power, it is unlikely to bias estimates. 
If data are not MCAR, then they are often classed as missing at random (MAR) or missing not 
at random (MNAR). Both are problematic as they will likely reduce power and bias estimates. 
MAR allows the probability of missing data for a variable 𝑋𝑋 to be dependent on other variables 
in the dataset but not on𝑋𝑋𝑖𝑖 , where i is the value of X for an individual observation. In the case 
of MNAR the probability of the data being missing will be dependent on the value of 𝑋𝑋𝑖𝑖  . 
MNAR data is difficult to address without further knowledge of the missing data, but MAR data 
can be addressed either through limiting analyses to subgroups related to the missing data 
pattern or via imputation processes. In practice it is often difficult to determine whether data 
are MAR or MNAR (4).     
 
Missing data for the degree-of-spread variable 1993-1998 
In normal circumstances, the ‘unknown’ category is a legitimate response for degree-of-spread 
and is coded by NSW CCR staff when the notifications received do not provide sufficient 
information to ascertain a degree of spread. The notifying party such as hospital or pathology 
lab may, given further testing/pathology, be able to determine degree of spread, but the NSW 
CCR coding staff,  are not privy to decision-making regarding further investigation.  
In the artefact period, there was an additional causal factor at play whereby the answer may 
have been known by the notifying party, but as there was no category for indicating degree of 
spread as ‘localised’ on the electronic notification system, this piece of information was not 
conveyed to the registry. This aligns most closely with cause (i) above – the question was not 
asked of the notifier, or cause (iv) the response was not able to be recorded.  
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In the period 1993-1998 all cases coded as ‘unknown’ based on electronic notifications (E or 
EM) are associated with an element of uncertainty. If the data collection problem had not 
existed then they may have been coded as localised rather than unknown. For E cases, all 
‘unknown’ cases could be considered missing. For EM cases, as some information was still 
received manually, a proportion of cases were likely to have been affected by the data 
collection issue with an unknown proportion unaffected. However, as there is an element of 
doubt associated with these values we could therefore consider all cases notified as unknown 
by E or EM means to be ‘missing’ rather than ‘unknown’.  From this point on, these cases will 
be referred to as ‘missing’ and the aim will be to re-distribute the cases to the categories 
‘unknown’ and ‘localised’ in a valid and informative manner.  
In the current situation we know the data is not MCAR, as the probability of missing data is 
known to be dependent on both year of diagnosis and notification method. We have 
knowledge of the missing data mechanism based on the knowledge of the introduction of the 
ENS in 1993 and the amendment of the system in 1999. However, particularly for cases that 
received both electronic and manual notifications in this period, the mechanism for identifying 
when adequate information was available for coding is not able to be clearly identified based 
on available data. While we assume that the missing data is MAR, there is a possibility that it is 
MNAR. It should be noted however, that the missingness of the localised or unknown degree-
of-spread category during the artefact period did not depend on whether the cancer’s true 
degree of spread was localised or unknown. In the current study, imputed data patterns will be 
assessed to determine the plausibility of the MAR assumption. Additionally, the MI model will 
be applied to data in a distinct time period with known values for localised and unknown to 
test the sensitivity of the model in a situation where the MAR assumption holds and one 
where it does not. Sensitivity analysis has been proposed as a useful technique to assess the 
appropriateness of the MAR assumption (4).   
 
Multiple Imputation to correct for missing data 
There are various ways of dealing with missing data in analyses. The most common method is 
complete case analysis, whereby only cases without missing data are included. In the current 
situation, this is not feasible due to both the number of cases that would be designated as 
missing and the relationship between missing data and both time period and notification 
method. A solution to the problem proposed by Barraclough et al. was to consider using 
grouped data only (eg. group unknown and localised cases together for this period). However, 
this limits any analyses that aim to investigate the effect or outcomes of localised cancer. 
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Alternatively, analyses could be limited to a time period outside the known artefact period, 
such as using cases diagnosed from 1999 onwards. Again this limits the types of analyses able 
to be undertaken as often trends over long time periods are required to examine 
epidemiological relationships.  
Imputation is a process by which the missing data are replaced with plausible values, often 
based on knowledge of other variables in the dataset. Single imputation can result in 
spuriously precise estimates. Multiple imputation takes into account the uncertainty 
introduced by estimating missing values. Generally only a small number of imputations 
(between 3 and 10) are required, and the inter-imputation variability can then be used to 
adjust the error component of subsequent analyses (5).    
It is known that the degree of spread variable is related to other variables within the CCR 
database and is commonly used to monitor differences in survival patterns for most cancers 
(6). For this reason, it is likely that a logistic regression model will provide a reasonable level of 
prediction of localised versus unknown cases. The next section examines potential predictive 
variables and then potential logistic regression models that could be used within the multiple 
imputation process.   
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Section 2: Building a predictive multivariate model for localised versus unknown 
degree of spread for lung cancer 
 
Assessing potential predictors of localised versus unknown degree of spread 
A range of variables in the CCR database were investigated to assess their association with 
localised versus unknown degree of spread. The first aim was to identify variables that were 
significant predictors of localised versus unknown degree of spread. Associations were 
assessed for all localised and unknown degree-or-spread lung cancers diagnosed in years 
either side of the artefact period (1986-1992 and 1999-2004) and for all notification methods. 
Lung cancer cases were identified based on ICD10 codes C33-C34. The decision was made to 
exclude all cases diagnosed by death certificate only as very limited information is available for 
these cases and degree of spread is nearly always unknown. There were 25,082 cases of 
unknown or localised lung cancer diagnosed between 1986-2004, of which 16,922 fell in the 
two periods 1986-1992 and 1999-2004. Within these latter periods, 50.5% were localised and 
49.5% were unknown. 
Given the relationship of the missing data to two factors – diagnosis period and notification 
method – the second aim was to assess the consistency of variables as predictors of degree of 
spread. Firstly, association with degree of spread was assessed across three time periods 
(1986-1992 – period 1; 1993-1998—period 2; and 1999-2004—period 3) within manual 
notifications only, and secondly, across each notification method for time period three (1999-
2004).   
There were 16,467 cases diagnosed from 1986-2004 notified by manual means only, of which 
44.4% were localised and 55.6% unknown. Of these cases, 53.3% were in period 1, 27.7% in 
period 2, and 19.0% in period 3. There were 8,002 cases diagnosed in period 3 across all 
notification methods with 50.5% localised and 49.5% unknown. Of these cases, 19.3% were 
based on electronic-only notifications, 41.6% on electronic and manual, and 39.1% on manual 
only.  
The variables investigated fell into three categories: (i) Basic demographic variables (age, sex, 
socioeconomic status, area health service of residence, Aboriginal and Torres Strait Islander 
status); (ii) Clinical variables (two-year survival, site of cancer, histology of cancer, number of 
primary cancers); and (iii) Registration variables (method of diagnosis, number of notification 
episodes, type of notifying institutions).  
A summary of the distribution of each variable by localised and unknown degree of spread is 
included in Appendix A. Based on initial analyses variables were re-categorised to try to 
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achieve the best consistency across time period and notification method. All continuous 
variables were categorised when non-linear associations with localised degree of spread were 
found to maximise consistency of association. An overview of the categorisation, association 
and consistency of each association for each variable is presented in table 1. 
Based on univariate analyses, all variables except sex and number of primary cancers were 
significantly related to localised degree of spread. However, there appeared to be seven 
variables that maintained consistent association over time: age group; socio-economic status 
of area of residence (highest quintile vs lowest four quintiles); area of residence at diagnosis 
(metro vs non-metro); survival status (alive>2yr vs died <2yr); site of cancer (Lung& Bronchus 
NOS vs other sites); method of diagnosis; and number of notification episodes. Only three of 
these variables remained consistent across notification method (area of residence, site of 
cancer and number of notification episodes).   
Building a multivariate logistic model 
The predictive value of variables and consistency of association at a univariate level provides 
some indication as to which variables may be reliably included in a predictive multivariate 
model. However, variables can behave in a different manner when included in a multivariate 
model due to their associations with other covariates. Therefore, a similar process was used to 
build and assess a logistic regression model as for assessing univariate predictors. The aim was 
to build a model that would: 
• Provide a reasonable level of prediction; 
• Be a good fit of the data; 
• Behave in a similar predictive manner independently of time period ; 
• Behave in a similar predictive manner independently of notification method (electronic 
versus manual) 
A “reasonable level of prediction” was assessed by examining the area under the ROC curve 
which indicates the combined sensitivity and specificity of the model. The aim was to achieve 
at least 70% prediction accuracy based on this measure.  
A “good fit of the data” was assessed by examining the Adjusted R-square values and by using 
the Hosmer and Lemeshow Goodness of fit test. 
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Table 1: Association and consistency of association of variables with localised degree of spread 
Predictor Description Categorisation 𝝌𝝌𝟐𝟐 
(p(𝝌𝝌𝟐𝟐)>0) 
Consistent 
across time 
periods 
within 
manual 
notifications 
Consistent 
across 
notification 
method 
within time 
period 3 
(1999-
2004) 
Demographic variables 
Age Group Age at diagnosis, categorised into 3 age groups <65 
65-74 
75+ 
215.1 
(P<0.01) 
yes No 
Sex Sex M 
F 
0.28 
(p=0.60) 
yes yes 
Socio-
economic 
status of 
area of 
residence at 
diagnosis 
Based on SEIFA Index of Relative Disadvantage 
for postcode of residence at the time of 
diagnosis. Indexes were available for the years 
1986, 1991, 1996, 2001, and 2006 and the 
closest index to the year of diagnosis was used. 
Data were grouped into quintiles. 
 
Highest quintile 
Lowest four quintiles 
64.5 
(p<0.01) 
yes yes 
Area of 
residence at 
diagnosis 
Based on postcode of residence at time of 
diagnosis, cases are coded to one of the 8 Area 
Health Services (AHS) of NSW (2005 definition). 
The AHS were then re-grouped as Metropolitan 
(Hunter & New England, North Coast, Greater 
Southern, Greater Western) and Non-
metropolitan (Sydney South West, South Eastern 
Sydney & Illawarra, Sydney West, Northern 
Sydney & Central Coast) 
Metropolitan 
Non-metropolitan 
237.3 
(p<0.01) 
yes yes 
ATSI status Cases are coded as ATSI, Non-ATSI and 
unknown. ATSI and non-ATSI were grouped due 
to low case numbers 
Known 
Not Known 
48.8 
(p<0.01) 
no no 
Clinical variables 
Two year 
survival 
All cause survival from time of diagnosis Died <2 yrs 
Alive >2yrs 
538.9 
(p<0.01) 
yes no 
Site of cancer Based on ICD10 categorisation at a four digit 
level. Grouped as Lung & Bronchus NOS (C349) 
and all other sites within the Tumour Group 
“Lung” (C339, C340-C348). 
Lung & Bronchus NOS 
All other sites 
1145.7 
(p<0.01) 
yes yes 
Histology 
group 
Based on ICD-03 categorisation. Small Cell 
cancers and all other non-specific codes grouped 
due to low case numbers.   
Squamous Cell 
Carcinoma (SCC) 
Adenocarcinoma 
Small Cell and Other 
110.8 
(p<0.01) 
no No 
Number of 
primary 
cancers 
Number of primary cancers recorded at 
diagnosis 
One 
Two or more 
0.17 
(p=0.68) 
yes yes 
Registration variables 
Method of 
diagnosis 
The method used to code clinical aspects of the 
cancer diagnosis. Other includes clinical, 
cytology, post-mortem reports but no 
histopathology. Cases based on death certificate 
only were excluded from the analyses.  
Histopathology 
sighted at CCR 
Histopathology 
Other 
1828.3 
(p<0.01) 
yes no 
Number of 
notification 
episodes 
Count of notification episodes received for that 
case 
One-two 
Three or more 
657.8 
(p<0.01) 
yes yes 
Notifying 
facility type 
Based type of notifying institution. Multiple 
episodes can be received from public and 
private hospitals, pathology labs, nursing homes, 
outpatient clinics. Grouped as cases including a 
private hospital notification and those not 
including a private hospital notification. 
Includes private 
Does not include 
private 
577.3 
(p<0.01) 
no no 
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By “behaving in a similar predictive manner” it is meant that variables included in the model 
must have the same relationship with the outcome variable regardless of time period or 
notification method (broadly speaking this means they are always positive predictors or always 
negative predictors). Ideally all variables should also have roughly the same magnitude of 
prediction in all situations (indicated by similar sized regression coefficients). However, a 
reasonable prediction consistency was considered to be satisfied if the covariates had the 
same direction of relationship, with potentially differing strengths of relationship.  
A full main effects logistic model (labelled Model 1) was initially assessed across 5 separate 
datasets: manually notified cases (M) for periods 1, 2, and 3; and for Electronic only (E) and 
Electronic plus manual (EM) cases within period 3. The results of these regression analyses are 
presented in tables B1 and B2 in Appendix B.  
Five variables were significant predictors after controlling for other factors and behaved 
reasonably consistently across time periods: age; area of residence at diagnosis; histology; site 
of cancer; survival; and method of diagnosis.  Four of these five were identified as consistent at 
a univariate level with histology now appearing as reasonably consistent across time after 
controlling for other factors. The number of notification episodes no longer appeared 
consistent after controlling for other factors.  
Area of residence at diagnosis, and site of cancer remained consistent across notification 
methods. 
As notification method appeared to interact with most variables in predicting localised degree 
of spread, the decision was made to just focus on data available in period 3, in which all three 
notification method groups were available with no missing data. This allows models to take 
into account differences across notification methods. However, given that the missing data 
exist in a distinct time period, only variables shown to behave consistently across time periods 
were considered for analysis. Two further models were assessed:  
• Model 2: a reduced main and interaction effects model including only significant and 
consistent variables as main effects and significant interaction terms. This model was 
applied separately to E and EM cases in period 3. 
• Model 3: the same as model 2, but including notification method as a main and 
interaction effect. This model was applied to a combined dataset of all E and EM cases 
in period 3.  
Proc Logistic within SAS version 9.2 was used for all analyses. 
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Results  
Table 2 and Figure 5 provide a summary of the results from Model 2 applied separately to E 
and EM notified cases within period 3. These models were shown to have reasonable 
predictive power, although they were borderline for meeting the predictive benchmark 
established a priori. The model for EM notified cases was slightly more predictive with 71.5% 
prediction accuracy based on the area under the ROC curve. This compared to 67.0% 
prediction accuracy for E notified cases. The model also provided a better fit of the data for EM 
cases compared to E only. Both provided an adequate fit of the data based on the Hosmer and 
Lemeshow Goodness of Fit test.    
Table 3 provides a summary of results from Model 3 for the E and EM combined dataset for 
period 3. Only one interaction effect with notification method remained significant (method of 
diagnosis by notification method) so others were excluded. This model appeared to have good 
predictive power at 76% based on the area under the ROC curve and was an adequate fit of 
the data.  
Direct comparison of the model diagnostics between Models 2 and 3 is difficult given that 
model 3 is based on a larger combined dataset.  
Both Models 2 and 3 appear to provide reasonable prediction for localised versus unknown 
degree of spread and fit the data adequately. While Model 3 is more parsimonious, both were 
applied within a multiple imputation procedure to test the viability of this process. Two major 
assumptions are made in applying these models to impute the missing data: 
1) The variables included within the model have the same predictive effect within E and 
EM cases in 1993-1998 as they do within 1999-2004 
2) The underlying proportions of localised and unknown cases in 1993-1999 are similar to 
those in 1999-2004. 
There is no direct way to test these two assumptions. However, to support the validity of 
assumption 1, only variables consistent across periods based on the manual notification group 
were included. Assumption 2 appears reasonable based on the finding that the proportions 
were similar for the periods before and after the 1993 to 1998 period. 
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Table 2: Logistic Regression results for predicting localised lung cancer: Model 2 applied to a) 
E notified cases and b) EM notified cases in period 3 
  
Model 2(a) Model2(b) 
  
E EM 
Parameter Reference category Estimate Pr > ChiSq Estimate Pr > ChiSq 
Intercept 
  
-0.95 <0.01 0.51 <0.01 
Histology Adenocarcinoma SCC -0.41 0.02 0.15 0.16 
 
Sm. Cell and other SCC -0.46 <0.01 -0.27 0.01 
Method Histo sighted at CCR Other -1.36 0.08 0.78 <0.01 
 
Histopathology Other 0.41 0.00 0.63 <0.01 
Site Bronchus & Lobes NOS Other 0.83 <0.01 -0.72 <0.01 
AHS Non-Metro Metro -0.26 0.02 -0.62 <0.01 
Survival alive > 2yr Died<2yr -0.85 <0.01 -0.08 0.80 
Survival*Method alive > 2yr*Histo-CCR Died<2yr*Other 2.77 0.01 1.24 0.00 
 
alive > 2yr* Histopathology Died<2yr*Other 1.11 <0.01 0.45 0.19 
       
  
Adj r squared 0.11 
 
0.160 
 
  
% Concordance 63.9 
 
69.4 
 
  
% Discordance 30.3 
 
26.3 
 
  
Goodness of fit 10.68 0.15 6.40 0.70 
 
Figure 5: ROC curve for Model 2 applied to a) E notified cases and b) EM notified cases in 
period 3 
 
 
  
(b) (a) 
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Table 3: Logistic Regression results for predicting localised lung cancer: Model 3 applied to E 
and EM notified cases in Period 3 
  
Model 3 
  
E and EM 
Parameter Reference category Estimate Pr > ChiSq 
Intercept 
  
0.58 <0.01 
Histology Adenocarcinoma SCC -0.01 0.90 
 
Sm. Cell and other SCC -0.34 <0.01 
Method Histo sighted at CCR Other 0.70 <0.01 
 
Histopathology Other 0.58 <0.01 
Site Bronchus & Lobes NOS Other -0.80 <0.01 
AHS Non-Metro Metro -0.48 <0.01 
Notification method E EM -0.70 <0.01 
Survival alive > 2yr Died<2yr -0.52 0.01 
Survival*Method alive > 2yr*Histo-CCR Died<2yr*Other 1.72 <0.01 
 
alive > 2yr* histopathology Died<2yr*Other 0.84 <0.01 
Notification 
method*Method 
E*Histo-CCR EM*Other 
-1.81 <0.01 
 
E* histopathology EM*Other -0.18 0.26 
     
  
Adj r squared 0.27 
 
  
% Concordance 75.3 
 
  
% Discordance 22.6 
 
  
Goodness of fit 12.43 0.19 
 
Figure 6: ROC curve for Model 3 applied to E and EM notified cases in Period 3 
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Section 3: Multiple Imputation to correct the degree-of-spread data artefact for lung 
cancer cases 
 
Imputation Procedure  
The multiple imputation procedure within SAS 9.2 was used to produce new datasets based on 
the two models being tested: Model 2 as specified in table 2 and Model 3 as specified in table 
3. Five imputations were undertaken on missing data by specifying each model using the 
logistic option within the MI procedure. For both models, the missing data were defined by 
creating a new variable for degree of spread which included original degree-of-spread values 
but was deemed ‘missing’ if:  
• the value of stage was ‘unknown’; and  
• the notification method was electronic or electronic and manual; and 
• the year of diagnosis was between 1993- 1998.   
A further restriction was placed on the MI procedure: the ‘prototype’ cases to be used for 
predicting the missing data were limited to only those cases diagnosed in the period 1999-
2004 by electronic only (E) or electronic plus manual (EM) means. To produce the imputed 
data using the MI procedure in SAS, only the prototype cases and the cases with missing 
degree-of-spread data were included.  
The MI process produces five datasets for each model representing the five iterations of the 
imputation process. An analysis dataset is created for each model which combines the five 
datasets and Proc MIAnalyze was used to combine estimates from the five imputed datasets.  
 
Results - Imputation 
Based on original coding the proportion of localised cases of lung cancer (within all localised 
and unknown) diagnosed in 1993-1998 was 32.0%. Following multiple imputation the 
proportion was 50.6% with a 95% Confidence Interval of 49.3 - 52.0%.  
Table 4 shows the proportion of unknown cases re-coded to localised following imputation. 
There was an increase in recoding from 1993-1997 which reflects the rapid increase in 
frequency of electronic notifications. The proportion of cases recoded by year was similar for 
both models. 
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Table 4: Percentage of unknown cases re-coded to localised following imputation, by year of 
diagnosis 
 
 1993 1994 1995 1996 1997 1998 
Model 2 % 21.9 26.2 28.0 29.8 30.3 26.7 
Model 3 % 22.5 26.9 27.4 29.6 31.2 26.9 
 
Figure 7 shows the percentages localised and unknown prior to any imputation and following 
imputation based on Model 2. The model appears to correct the artefact. Figure 8 shows the 
same following imputation based on Model 3. This model also appears to correct the artefact, 
following a very similar trend as per Model 2. Figure 9 compares the two models, and shows 
that the results are almost identical.  
Given the similarities between the two models, Model 3 was the more parsimonious and was 
the preferred model for further investigations.  
 
Figure 7: Model 2 – percentage localised and unknown pre and post imputation 
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Figure 8: Model 3 – percentage localised and unknown, pre and post imputation 
 
Figure 9: Percentage localised pre- imputation and post- imputation, Models 2 and 3 
 
 
Validation of the MI model 
The results produced using MI are plausible in terms of correcting the data artefact. However, 
due to the missing data pattern, some major assumptions were required to implement this 
procedure. The missing data for degree of spread were for all E and EM cases within a distinct 
time period. Additionally, method of notification appeared highly related to degree of spread. 
This meant that manually notified cases within the time period 1993-1998 were not deemed 
appropriate cases upon which to base a model predicting missing data in E and EM cases. 
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Instead cases within a distinct time period for just E and EM cases were used. In doing so, we 
are assuming that the relationships between predictors and degree of spread within the E and 
EM groups are the same within the 1993-1998 period as they are within the 1999-2004 period. 
We are also assuming that the ratio of localised to unknown cases is similar in the two periods.   
Two additional sets of analyses were undertaken to assess the validity of the imputation 
model. Firstly, the effect of imputation by covariates was examined to identify any potential 
biases introduced within sub-groups. Secondly, the same MI process using 1999-2004 cases 
was applied to predict all localised and unknown E and EM data in the period 2005-2006. This 
enabled direct comparison between actual values and predicted values. While it does not 
directly assess the assumptions made for the period 1993-1998 it provides an alternate 
mechanism for testing the validity of applying the model in a different time period.  
 
Results - validation 
Imputed data patterns by covariate 
The effect of imputation by covariates is presented for Model 3 in figures 10(a)-(f). The effect 
of imputation appears consistent across all levels of covariates with the exception of Method 
of diagnosis = ‘Other’. For this grouping there appears to be a possible ‘over-compensation’ 
with an increase in proportion localised during the artefact period. However, closer analysis of 
this grouping by method of notification (figure 11) shows that there was an increase in 
proportion localised for manually notified cases also, which suggests that other factors may 
have influenced this trend. 
 
Figure 10a: Model 3 – pre and post imputation by NOTIFICATION METHOD 
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Figure 10b: Model 3 – pre and post imputation by METHOD of DIAGNOSIS 
 
Figure 10c: Model 3 – pre and post imputation by SURVIVAL 
 
Figure 10d: Model 3 – pre and post imputation by HISTOLOGY 
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Figure 10e: Model 3 – pre and post imputation by SITE of LUNG CANCER 
 
Figure 10f: Model 3 – pre and post imputation by AREA 
 
Figure 11: Model 3 – pre and post imputation by NOTIFICATION METHOD for METHOD of 
DIAGNOSIS = Other 
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Two scenarios were tested using cases diagnosed within 2005-2006. Firstly, a sample of 1,000 
test cases was randomly selected from all E and EM notified localised and unknown cases 
within this period. These test cases reflected the underlying proportion of 53.8% localised 
versus 46.2% unknown degree of spread for these years. This was a different proportional split 
from the ‘prototype’ cases within the period 1999-2004 in which 60.7% were localised. 
Secondly, a sample of test cases was purposefully selected to ensure the proportion localised 
matched that of the prototype cases (with 60.7% localised). 
The test cases were designated as having missing data for degree of spread. Data was then 
multiply imputed for the degree-of-spread variable for test cases and imputed values 
compared with original ‘known’ values.   
Table 5 indicates the effectiveness of the MI model in correctly predicting cases of unknown 
and localised cases (E and EM notified) for the period 2005-2006 based on scenario 1.  
Prediction was reasonable for localised cases, with the model correctly predicting 69.0% with a 
95% confidence interval of 63.7-74.4% based on the multiply imputed datasets. In terms of 
predicting localised cases, this shows the model as having high sensitivity. However, the model 
was poor for predicting unknown degree-of-spread cases, only correctly predicting 48.3% (95% 
CI: 42.8-52.8%) showing poor specificity.  
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Table 5: prediction of E and EM notified, localised and unknown cancers for 2005-2006 
    Original Coding 
    Localised 
Not Localised 
(Unknown) All cases 
Test 
Outcome 
Localised 371 239 610 
Not Localised (Unknown) 167 223 390 
All cases 538 462 1000 
          
 
Sensitivity (prediction of localised) 69.0% 
    Specificity (prediction of unknown) 48.3% 
 
  
 
Table 6 presents the results from this analysis based on scenario 2. For scenario 2, the data is 
missing at random, as the probability of a case being localised within the sample is 
independent of whether the missing data are included or excluded. The predictive power for 
localised cases is 69.5% (95% CI: (63.1-76.0), which is similar to that found within scenario 1. 
Again, the specificity is poor at 48.2% (95% CI: 40.0-59.4).  
 
Table 6: Prediction accuracy for E and EM notified, localised and unknown cancers – 2005-
2006, sample meeting the MAR assumption 
    Original Coding 
    Localised 
Not Localised 
(Unknown) All cases 
Test 
Outcome 
Localised 422 204 626 
Not Localised (Unknown) 185 190 375 
All cases 607 394 1000 
          
 
Sensitivity (prediction of localised) 69.5% 
    Specificity (prediction of unknown) 48.2% 
 
  
 
Overall, the model appeared to predict localised cases with reasonable sensitivity in a distinct 
time period. However specificity of the model was poor. These data suggest that the model 
performs moderately in a distinct time period but does not perform as well as it does in the 
1999-2004 period on which it is based. The results of this validation showed that prediction 
accuracy was not affected to a large extent by differing proportions of localised versus 
unknown degree of spread in the test period.   
The results of this validation suggest that caution should be exercised in applying this 
procedure in the manner described and the assumptions inherent in the process should be 
clearly articulated.     
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Section 4: Impact of correcting the data artefact on survival estimates  
 
Due to the relationship between survival and degree of spread, it is likely the data artefact will 
have impacted upon this type of analysis. To assess whether the data artefact could impact 
survival estimates, trends in survival by time of diagnosis were examined using the original 
pre-imputation data.  
For localised cases, Kaplan-Meier survival curves were computed by three year period based 
on original degree-of-spread coding (Figure 12a). The two time-of-diagnosis periods within the 
artefact period – 1993-1995 and 1996-1998 – had the third lowest and lowest mortality rates, 
with median survival of 20 and 27 months respectively. This is out of step with the overall 
pattern of survival across time periods, where there is evidence of a trend towards increasing 
survival over time with median time to death of 12, 13, 18 and 21 months for the periods 
1986-89, 1990-92, 1999-01, and 2002-04 respectively. For regionalised cancers, which were 
unaffected by the artefact, a similar trend in increasing survival is evident across all six time 
periods (Figure 13).   
Post-imputation, the survival trend across time for localised cancers appears more in 
accordance with that seen for regionalised cancers, with survival increasing uniformly with 
each time period (Figure 12b). Comparing the survival curve for localised cases pre and post 
imputation for the artefact period (1993-1998), we can see that survival is significantly lower 
following imputation (Figure 14a). Based on originally coded data, median time to death was 
23 months (95% CI 22-24), which reduced to 15 months (95% CI 15-16) based on imputed data.   
Survival from lung cancers diagnosed with ‘unknown’ degree of spread was not similarly 
affected by the data artefact, with very little difference in survival evident across time periods 
and imputation had little impact on estimates for the artefact period (Figure 14b). Median 
survival from unknown lung cancer diagnosed within the period 1993-1998 was 9 months 
based on original data and 8 months based on imputed data, which was not significantly 
different (p=0.23).    
The reason for the difference in impact of imputation for localised cancers compared to 
unknown cancers can be explained by the differences in survival by degree of spread and 
notification method. Based on data from 1999-2004 for localised cancers diagnosed within the 
M group, survival appears substantially better than for both the E and EM groups (Figure 15a). 
However, for cases with unknown degree of spread, survival differences by notification 
method were substantially less (Figure 15b). This means that when cases from the E and EM 
groups are re-categorised from unknown to ‘localised’ they tended to be cases with worse 
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survival than those in the M group and therefore reduced the survival rate of the group as a 
whole.  
This may be linked to the fact that pathology reports (which are manual notifications) are 
generally received for lung cancer when surgery has been undertaken, and that surgery for 
localised lung cancer is an indicator of better outcomes (7).   
 
Figure 12a : Kaplan-Meier survival curve for lung cancer cases with localised degree of 
spread, by period of diagnosis, PRE-IMPUTATION 
 
Figure 12b: Kaplan-Meier survival curve for lung cancer cases with localised degree of 
spread, by period, POST-IMPUTATION 
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Figure 13: Kaplan-Meier survival curve for lung cancer cases with regionalised degree of 
spread, by period of diagnosis 
 
 
Figure 14a : Kaplan-Meier survival curve for lung cancer cases diagnosed 1993-1998 with 
localised degree of spread, Pre- and Post- imputation 
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Figure 14b : Kaplan-Meier survival curve for lung cancer cases diagnosed 1993-1998 with 
unknown degree of spread, Pre- and Post- imputation 
 
Figure 15a : Kaplan-Meier survival curve for lung cancer cases diagnosed 1999-2004 with 
localised degree of spread, by notification method 
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Figure 15b : Kaplan-Meier survival curve for lung cancer cases diagnosed 1999-2004 with 
unknown degree of spread, by notification method 
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Section 5: Discussion and Conclusions 
 
The MI procedure using the logistic option based on model 3 appears to provide a reasonable 
approach to correcting the data artefact for degree of spread for lung cancer. Plausible results 
were produced that are consistent across levels of other covariates in the database. This 
model requires that cases are categorised into groups based on method of notification, but 
aside from this relies only on readily available variables within the CCR reporting database. 
The data artefact that currently exists for the period 1993-1998 appears to significantly impact 
on survival from localised lung cancer for this period. Correction of the data artefact based on 
the imputation process used here produces significantly lower survival estimates for localised 
lung cancer cases within the 1993-1998 period; however, survival trends by time of diagnosis 
appear more consistent. The imputation process did not appear to impact on survival 
estimates for unknown cases.  
In order to implement this procedure, cases recorded originally as having unknown degree of 
spread were designated as “missing” for all Electronic (E) and Electronic plus manual (EM) 
notifications within a distinct time period (1993-1998) based on year of diagnosis. This meant 
that the predictive model had to be based either on cases notified by a different means 
(manual only), or on cases notified within a different time period (1999-2004). Given the 
observed differences in ratio of localised-to-unknown cases for different methods of 
notification, the chosen approach was to use cases from a different time period for E and EM 
notifications only. Two major assumptions are therefore made: the overall ratio of localised to 
unknown cases is similar across time periods; and the relationship between predictors and 
localised degree of spread within the E and EM groups are the same within the 1993-1998 
period as they are within the 1999-2004 period.  
Validation of the chosen imputation process using cases from 1999-2004, but applied to cases 
diagnosed in a independent time period (2005-2006) with known degree-of-spread coding, 
suggested that the model still had an adequate ability to predict localised cases. However, the 
results suggested that some sensitivity and specificity was lost since model parameter 
estimates developed from the 1999-2004 period were applied to 2005-06.  
The MI procedure appears a useful approach to correcting the known data artefact for degree 
of spread in lung cancer. However, given the major assumptions made and level of prediction 
achieved, it is recommended that caution is applied in using the imputed data. While values 
appear plausible when examined holistically and across broad levels of covariates, it is not 
considered appropriate to use the data at a case level.  For analyses of small sub-groups 
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further investigation of the validity of this model would be required. In all instances, 
appropriate methods should be used to account for the increased error that is introduced via 
imputation.  
This study describes the application of this procedure to one cancer type – lung cancer. The 
data artefact in the NSW Central Cancer Registry is known to exist to varying degrees for all 
solid tumours, excepting breast and melanoma. The model used here includes some variables 
that are specific to lung cancer, including ‘site of cancer’ and ‘histology’ of cancer. For both 
these variables there appeared to be a relationship between categories that were non-specific 
such as ‘not otherwise specified’ and the increased likelihood of ‘unknown’ degree of spread. 
For this reason, it is likely that these variables will remain useful predictors for other cancer 
types, but categories would need to be specified on a cancer-by-cancer basis.   
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Appendix A: Summary of potential predictors for degree of spread 
 
Demographic variables 
Age 
Age was significantly associated with unknown versus localised degree of spread. The mean 
age of localised cases was 68.3 years which was lower than for cases with unknown degree of 
spread (70.8 years) (t=-19.3; p<0.01). Age did not appear to be linearly related to degree of 
spread with those in the 75+ age group showing much lower levels of localised cancer than 
those in younger age groups. The effect of age appeared reasonably consistent across time, 
but not across notification methods. Due to the non-linear association, age was treated as a 
categorical variable for further analyses.  
Figure A1: Age distribution for localised and unknown cases  
 
Figure A2: proportion localised by age group: (a) by period of diagnosis for M notified cases; 
(b) by notification method within period 3 
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Sex 
Sex of patient was not significantly associated with degree of spread of lung cancer at 
diagnosis (𝜒𝜒2 = 0.28, p=0.60).  
Table A1: Distribution of Localised and Unknown cases, by sex 
Sex 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Female N 2567 2546 5113 
0.60 
 % 50.2 49.8   
Male N 5981 5828 11809 
 % 50.6 49.4   
 
There was very little difference between males and females in all periods and across all 
notification methods.  
Figure A3: proportion localised by sex: (a) by period of diagnosis for M notified cases; (b) by 
notification method within period 3 
  
 
 
Socio-economic status 
Socio-economic status (SES) was measured by SEIFA Index of Relative Disadvantage for 
postcode of residence at the time of diagnosis. Indexes were available for the years 1986, 
1991, 1996, 2001, and 2006 and the closest index to the year of diagnosis was used. Data was 
grouped into SEIFA quintiles. SES showed a significant association with degree of spread 
(𝜒𝜒2 = 98.69, p=<0.01). The proportion of cases with unknown degree of spread was highest in 
the second lowest SES quintile and tended to lower proportions in the higher SES quintiles. 
There were also a small number of cases for which SES was undetermined due to missing 
postcode information.  
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Table A2: Distribution of Localised and Unknown cases, by socio-economic status 
IRSAD quintile 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Lowest N 1960 1962 3922 
<0.01 
 % 50.0 50.0   
Second N 1781 2058 3839 
 % 46.4 53.6   
Third N 1682 1825 3507 
 % 48.0 52.0   
Fourth N 1579 1392 2971 
 % 53.1 46.9   
Highest N 1507 1103 2610 
 % 57.7 42.3   
Unknown N 39 34 73 
 % 53.4 46.6   
 
When considering manual notifications only, the association between SES and degree of 
spread was reasonably consistent across periods. The majority of difference in percentage 
localised appears to be occurring for the highest quintile compared to the lowest four. There 
was little difference between the lowest three quintiles in all periods and, within period 3, 
there was little difference between the lowest four quintiles across all notification methods. 
For this reason, the four lowest categories were collapsed for multivariate analyses. 
 
Figure A4: proportion localised by SES: (a) by period of diagnosis for M notified cases; (b) by 
notification method within period 3 
  
 
Area Health Service (AHS) of Residence at time of diagnosis 
AHS at diagnosis showed a significant association with degree of spread (𝜒𝜒2 =383.1, p=<0.01). The non-metropolitan areas (Hunter New England, North Coast, Greater 
Western and Greater Southern) had the highest proportion of unknown degree of spread 
cases. The areas were re-grouped for further analyses as metropolitan and non-metropolitan 
areas. Metropolitan areas showed consistently higher percentages of localised cases across 
period and notification methods. 
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Table A3: Distribution of Localised and Unknown cases, by Area Health Service of residence 
AHS of residence 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
South Western Sydney n 1756 1355 3111 
<0.01 
  % 56.4 43.6  
South Eastern Sydney/ Illawarra n 1531 1531 3062 
  % 50.0 50.0  
Western Sydney n 1266 852 2118 
  % 59.8 40.2  
Northern Sydney/ Central Coast n 1380 1122 2502 
  % 55.2 44.8  
Hunter / New England N 1219 1271 2490 
  % 49.0 51.0  
North Coast N 516 1022 1538 
  % 33.5 66.5  
Greater Southern N 523 728 1251 
  % 41.8 58.2  
Greater Western N 355 493 848 
  % 41.9 58.1  
Unknown N <5 - <5 
  % 100 0 100 
 
Figure A5: proportion localised by AHS: (a) by period of diagnosis for M notified cases; (b) by 
notification method within period 3 
  
 
Aboriginal/ Torres Strait Islander (ATSI) status 
 
ATSI status is known to be under-reported in the CCR, but is recorded where sufficient 
information is available. “Unknown” ATSI status was treated as a separate category of interest. 
ATSI status was significantly associated with the proportion of unknown versus localised 
degree of spread cases (𝜒𝜒2 = 49.08 , p=<0.01). Those persons of ATSI background had higher 
proportions of unknown degree of spread compared to those known to be non-ATSI. For those 
with unknown ATSI status there was an even higher proportion of unknown degree of spread 
cases.  Due to low cell sizes, for further analyses, ATSI and Not ATSI were grouped as “known”. 
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There were distinct differences in the pattern of association across time periods and 
notification methods based on this re-grouping.  
Table A4: Distribution of Localised and Unknown cases, by ATSI status 
ATSI status 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
ATSI n 45 44 89 
<0.01 
 % 50.6 49.4   
Not ATSI n 4481 3940 8421 
 % 53.2 46.8   
Unknown n 4022 4390 8412 
 % 47.8 52.2   
 
Figure A6: proportion localised by ATSI status: (a) by period of diagnosis for M notified cases; 
(b) by notification method within period 3  
 
Two Year Survival 
Two year survival was significantly associated with degree of spread with those surviving to 2 
years more likely to have localised degree of spread compared to unknown degree of spread 
(𝜒𝜒2 = 538.92, p<0.01).  
Table A5: Distribution of Localised and Unknown cases, by two year survival status 
Two Year Survival 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Did not survive to 2 years n 5546 6764 12310 
<0.01 
 % 45.1 54.9   
Survived to 2 years n 3002 1610 4612 
 % 65.1 34.9   
 
The association between two year survival and degree of spread was reasonably consistent 
across periods with the magnitude of effect increasing in later periods. However, the effect 
was inconsistent across notification methods, showing no effect within electronic only and a 
substantial effect within EM and M categories. 
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Figure A7: proportion localised by survival status: (a) by period of diagnosis for M notified 
cases; (b) by notification method within period 3 
  
 
Site of Cancer 
The site of the cancer within the lung was significantly associated with degree of spread 
(𝜒𝜒2 = 1228.1, p<0.01). Cancers of the lung and bronchus that could not be otherwise specified 
(NOS) to a site were associated with much higher proportions of unknown compared to 
localised degree of spread. For further analyses, this NOS category was compared against a 
grouping of all other sites. This re-categorisation appeared to produce consistent effects across 
both diagnosis period and notification methods. 
 
Table A6: Distribution of Localised and Unknown cases, by site of Lung cancer 
Site of Cancer 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Trachea n 27 20 47 
<0.01 
 % 57.4 42.6   
Main Bronchus n 751 577 1328 
 % 56.6 43.4   
Upper Lobe n 3464 2135 5599 
 % 61.9 38.1   
Middle Lobe n 359 258 617 
 % 58.2 41.8   
Lower Lobe n 1659 1004 2663 
 % 62.3 37.7   
Overlapping Lesion n 83 39 122 
 % 68.0 32.0   
Lung and Bronchus NOS n 2205 4341 6546 
 % 33.7 66.3   
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Figure A8: proportion localised by site of cancer: (a) by period of diagnosis for M notified 
cases; (b) by notification method within period 3 
 
 
Histology 
Cancers of the lung were grouped as Squamous Cell Carcinomas, Adenocarcinomas or Small-
cell carcinoma. Histology group was significantly associated with degree of spread (𝜒𝜒2 =162.5, p=<0.01). Squamous cell carcinomas were most likely to have unknown degree of 
spread with adenocarcinomas most likely to have localised degree of spread. The effect of 
histology did not appear to be consistent over time or notification method. 
 
Table A7: Distribution of Localised and Unknown cases, by histology 
  
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Squamous cell carcinoma n 5308 5588 10896 
<0.01 
 % 48.7 51.3   
Adenocarcinoma n 2112 1518 3630 
 % 58.2 41.8   
Small-cell  carcinoma n 1023 1017 2040 
 % 50.1 49.9   
Other n 105 251 356 
 % 29.5 70.5   
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Figure A9: proportion localised by histology: (a) by period of diagnosis for M notified cases; 
(b) by notification method within period 3 
  
 
Registration variables 
 
Number of primary cancers 
The number of primary cancers per person was not significantly associated with unknown 
versus localised degree of spread (𝜒𝜒2 = 0.17, p=0.68). This variable showed slightly more 
association within period 2, but overall appeared to consistently show no or weak association 
with degree of spread across period and notification method.  
 
Table A8: Distribution of Localised and Unknown cases, by number of primary cancers 
Number of primary cancers 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
1 n 7253 7086 14339 
0.68 
 % 50.6 49.4   
2 or more n 1295 1288 2583 
 % 50.1 49.9   
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Figure A10: proportion localised by number of primary cancers: (a) by period of diagnosis for 
M notified cases; (b) by notification method within period 3 
 
 
Method of diagnosis 
Method of diagnosis showed a highly significant association with degree of spread (𝜒𝜒2 =657.8, p=<0.01). If diagnosis was based on methods such as cytology only, clinical notes, 
imaging or biochemistry only (grouped as other), it was more likely that degree of spread was 
coded as “unknown”. If histopathology was available and particularly if the histology was 
sighted by staff at the Central Cancer Registry then it was much less likely that a cancer was 
coded as unknown. 
This variable demonstrated reasonably consistent effect across period but not across 
notification methods. Histology being sighted within the CCR was related to a higher degree of 
localised cancers for both EM and M notified cancers but not for E notified cases in period 3.  
Table A9: Distribution of Localised and Unknown cases, by Method of diagnosis  
Method of diagnosis 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Other n 996 3247 4243 
<0.01 
 % 23.5 76.5   
Histopathology  n 2939 2610 5549 
 % 53.0 47.0   
Histo sighted at CCR n 4613 2517 7130 
 % 64.7 35.3   
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Figure A11: proportion localised by method of diagnosis: (a) by period of diagnosis for M 
notified cases; (b) by notification method within period 3 
 
 
Number of Notification Episodes 
Number of notification episodes was categorised as “one-two” and “three or more”. Initial 
examination of association suggested that there was most difference between receiving only 
one notification versus receiving multiple notifications. However, the notification method 
grouping of electronic plus manual by definition requires at least two notification episodes, so 
maintaining a single notification category or treating this variable as continuous would be 
problematic. Based on this grouping, the number of notification episodes received was 
significantly related to degree of spread (𝜒𝜒2 = 1828.3 , p=<0.01). Having received three or 
more notifications compared to one or two only was associated with a higher proportion of 
localised cases.   
This variable behaved reasonably consistently across both period of diagnosis and notification 
method. 
Table A10: Distribution of Localised and Unknown cases, by number of notification episodes 
No. notification episodes 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
One-Two n 3304 4887 8191 
 
 % 40.3 59.7   
Three or more n 5244 3487 8731 
 % 60.1 39.9   
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Figure A12: proportion localised by number of notification episodes: (a) by period of 
diagnosis for M notified cases; (b) by notification method within period 3 
 
 
Notification – Facility type 
Multiple notifications could be received regarding a single cancer case and these could come 
from many different types of notifying institutions, including public hospitals, private hospitals, 
pathology labs and nursing homes. As there were many different combinations of responses 
possible, these were rationalised into three mutually exclusive groupings: those that included a 
private hospital notification; those that included a public hospital notification (but no private); 
and those that included neither a public or private hospital notification (classed as other).  
The type of facility type grouping submitting the notification(s) was significantly related to 
degree of spread (𝜒𝜒2 = 577.3 , p=<0.01). If a notification was received from a private hospital, 
the degree of spread was most likely to be localised, with cases where no hospital (public or 
private) provided a notification much more likely to be “unknown”. Facility type was related to 
notification method with “other” notifications always submitted manually. For this reason, 
categories were re-grouped as “includes private” and “does not include private”. 
This variable did not appear to behave consistently across period or notification method.  
Table A11: Distribution of Localised and Unknown cases, by notifying facility type   
Notification – Facility type 
 
Localised Unknown 
Total (localised 
+ unknown) P value (𝜒𝜒2) 
Includes public but no private n 7374 6936 14310 
<0.01 
 % 51.5 48.5   
Includes private n 1032 629 1661 
 % 62.1 37.9   
Other (no public or private) n 142 809 951 
 % 14.9 85.1   
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Figure A13: proportion localised by types of notifying facility: (a) by period of diagnosis for M 
notified cases; (b) by notification method within period 3 
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Appendix B: Logistic Regression results for full model (model 1) 
Table B1: Logistic Regression results for Model 1 applied to M notified cases in a) 1986-1992, b) 1993-1998 c) 1999-2004 
    Model 1 
Consistent 
across 
period 
    M - 1986-1992 M - 1993-1998 M - 1999-2004 
Parameter 
Reference 
category Estimate Pr > ChiSq Estimate Pr > ChiSq Estimate Pr > ChiSq 
Intercept 
  
-0.17 0.02 -0.28 0.00 -0.76 <.0001 
 
Age Group 65-74 <65 0.05 0.14 0.03 0.51 0.02 0.73 
yes 
 
75+ <65 -0.14 0.00 -0.07 0.19 0.00 0.97 
Sex F M -0.04 0.11 0.03 0.48 0.07 0.15 yes 
SES Other Highest -0.13 0.00 -0.17 0.00 0.03 0.66 no 
Area of Residence Non-metro Metro 0.16 <.0001 0.26 <.0001 0.23 <.0001 yes 
ATSI status Known Not known 0.15 0.00 -0.09 0.05 -0.02 0.73 no 
Survival alive > 2yr Died<2yr 0.15 <.0001 0.39 <.0001 0.47 <.0001 yes 
Histology Adenocarcinoma SCC -0.26 <.0001 -0.38 <.0001 -0.43 <.0001 
yes 
 
Sm. Cell and other SCC 0.04 0.30 0.28 <.0001 0.34 <.0001 
Site 
Bronchus & Lobes 
NOS 
Other -0.07 0.11 -0.29 0.00 -0.51 <.0001 yes 
Number Primary 
Cancers 
One Two + 0.01 0.70 -0.01 0.75 0.07 0.21 yes 
Method Histo sighted at CCR Other 0.46 <.0001 0.42 <.0001 0.69 <.0001 
yes 
 
Histopathology Other 0.37 <.0001 0.08 0.16 0.15 0.04 
Episodes One-two Three + -0.16 <.0001 -0.11 0.00 0.11 0.03 no 
Facility type Includes private No private -0.20 0.00 0.15 0.00 0.59 <.0001 no 
                    
  
Adj r squared 0.18 
 
0.25 
 
0.39 
  
  
% Concordance 70.2 
 
75.4 
 
82.3 
  
  
% Discordance 29.2 
 
24.2 
 
17.5 
  
    Goodness of fit 21.38 0.01 18.40 0.02 19.95 0.01   
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TableB2: Logistic Regression results for Model 1 applied to a) M notified cases, b) EM notified cases and c) E notified cases in period 3 
    Model 1 
Consistent 
across 
notification 
method 
    M - 1999-2004 EM - 1999-2004 E - 1999-2004 
Parameter 
Reference 
category Estimate Pr > ChiSq Estimate Pr > ChiSq Estimate Pr > ChiSq 
Intercept 
  
-0.76 <.0001 0.01 0.98 -1.20 0.02 
 
Age Group 65-74 <65 0.02 0.73 0.02 0.75 0.03 0.70 
yes 
 
75+ <65 0.00 0.97 0.03 0.60 0.13 0.10 
Sex F M 0.07 0.15 0.03 0.49 -0.01 0.86 no 
SES Other Highest 0.03 0.66 -0.01 0.87 -0.17 0.05 no 
Area of Residence Non-metro Metro 0.23 <.0001 0.30 <.0001 0.09 0.14 yes 
ATSI status Known Not known -0.02 0.73 0.65 0.05 0.06 0.90 yes 
Survival alive > 2yr Died<2yr 0.47 <.0001 0.39 <.0001 -0.03 0.69 no 
Histology Adenocarcinoma SCC -0.43 <.0001 -0.35 <.0001 -0.45 <.0001 
no 
 
Sm. Cell and other SCC 0.34 <.0001 0.21 0.00 -0.11 0.37 
Site 
Bronchus & Lobes 
NOS 
Other -0.51 <.0001 -0.26 0.00 -0.17 0.13 yes 
Number Primary 
Cancers 
One Two + 0.07 0.21 0.09 0.10 0.11 0.12 yes 
Method Histo sighted at CCR Other 0.69 <.0001 0.43 <.0001 -0.19 0.53 
no 
 
Histopathology Other 0.15 0.04 0.10 0.08 0.41 0.01 
Episodes One-two Three + 0.11 0.03 -0.10 0.08 0.01 0.92 no 
Facility type Includes private No private 0.59 <.0001 0.14 0.03 -0.26 0.27 no 
                    
  
Adj r squared 0.39 
 
0.16 
 
0.11 
  
  
% Concordance 82.3 
 
71.4 
 
66.8 
  
  
% Discordance 17.5 
 
28.1 
 
32.5 
  
    Goodness of fit 19.95 0.01 15.51 0.05 19.12 0.01   
 
